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NOVEL THERMAL ANALYTICAL TECHNIQUES TO CHARACTERIZE
DRUGS AND DRUG DELIVERY
LAKSHMI SWETHA KAZA
ABSTRACT
This thesis encompasses three significant projects. The study includes the
characterization and evaluation of the properties of a commercial contraceptive
transdermal patch, Ortho Evra® by Dielectric Analysis and Differential Scanning
Calorimetry (DSC). This study helps in monitoring the mobility of the drug and transport
properties by Isothermal and Scanning Dielectric Analysis as a function of temperature
and frequency. The drugs in this product are norelgestromin and ethinyl estradiol. DSC
was used to detect any crystalline character of the drugs by their fusion properties.
Having no melting endotherm and detecting a glass transition temperature suggested that
the drugs in the patches were amorphous. The amorphous form of the drug has more
bioavailability. The isothermal DEA a plot of Log frequency vs. reciprocal temperature
(K) revealed two critical modulating frequencies at body temperature 37°C for the
two API drugs with DEA peak frequencies at 460 and 560 Hz.
The main project includes studying the polarization of macro and micro molecular
liquid drugs by Dielectric Analysis, B-Cell (a customized isothermal dielectric device)
and Differential Scanning Calorimetry. This study demonstrated in vitro transport of
selected non-ionic high (e.g. insulin) and low (e.g. Diphenhydramine) molecular weight
drugs through excised biological tissue membranes using alternating current (AC)
electrokinetics. This new technique of the drug delivery system enhances benefits over
systemic oral therapies, in which clinically sufficient quantities of the active ingredient
iv

do not reach the intended target organ and/or use of the drugs result in serious side
effects. An optimally-tuned low-voltage applied AC electrical field has been found
capable of inducing polarization and delivering micro and macromolecules through a
biological membrane. The relationships between factors such as delivery time, AC
voltage amplitude and frequency, and transported drug concentration were investigated.
A factorial design was used to establish experimental parameters for the insulin solution
evaluating DEA variables of voltage, frequency, time, temperature, drug dose, and
membrane thickness. A clear result of the experimental design for insulin was that the
low frequency was significant in enhanced drug delivery. Dielectric Analysis was used to
modulate the drugs delivery response measured by a change in the log conductivity vs.
log frequency curve at a lower frequency of 500 Hz and a higher frequency of 1000 Hz
for insulin at 37ºC. Imposition of a low frequency of 500 Hz aliened dipoles and higher
frequency aided the mobility of the drug ions into the biomembranes. The delivery was
confirmed qualitatively and quantitatively by enhanced conductivity for the drugs based
on the ―polaron theory‖ of conductivity or the ―hopping model‖ and UV spectroscopy.
The third project includes a study to develop a standard protocol to determine the
water content and type by thermal analysis of Milk of Magnesia. Differential Scanning
Calorimetry (DSC) and Thermal Gravimetric Analysis (TGA) were used in a novel
manner for examining the commercial pharmaceutical suspensions and to note the
difference between the brand and the generic forms.
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OBJECTIVES
The main objective of this thesis was to study the polarization of macro
and micro molecular liquid drugs by Dielectric Analysis, a customized B-Cell and
Differential Scanning Calorimetry. Evaluation of a commercial contraceptive transdermal
patch, Ortho Evra® using DEA aided in monitoring the mobility and transport properties
of the two drugs transdermally. DSC supplied information on the amorphous content of
the drugs, the low density polyethylene backing substrate that melted at 106oC, and the
Tg at -20oC of the adhesive suggests styrene butadiene rubber (SBR) latex in a low
molecular weight resin.
The delivery of the drug was confirmed quantitatively by recording the enhanced
conductivity of the drug in the bio-membrane and the drug throughput by calibrated UV
analysis. DEA was used to modulate the drugs delivery response measured by a change
in the log conductivity vs. log frequency curve at a low and a higher frequency. The
consequence of this Ortho Evra research helps in developing an AC electrified
transdermal patch for Diabetic patients in which there is a controlled release of insulin to
be associated with a consumer‘s blood glucose level.
Thermal Analysis aided in the development of a protocol to distinguish the water
content in the brand and generic forms of commercially available Milk of Magnesia
suspension and by difference in the total mass minus the water content revealed the
magnesium hydroxide content.
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HYPOTHESIS
The transdermal route provides continuous mode of administration of the drug
especially for protein and peptides having short half-lives. Skin is low in proteolytic
activity thus minimizing the degradation of the drug at the site of administration.
Transdermal patches are available in market for various drugs, but are limited to small
lipophilic molecules which can passively diffuse through the skin. Hydrophilic and
macromolecular drugs have low skin permeability in which electrical forces aids in drug
transport across the skin. Iontophoresis which uses Direct current (DC) is the most
commonly used electrical forces for transdermal patches. A number of adverse effects are
reported as a result of high applied voltages causing skin irritation and erythema.
However, this approach results in uncomfortably long treatment times. Iontophoresis
replaced by AC electric field would be a novel method for the drug delivery minimizing
the adverse effects. It is important to have a sensitive method to characterize the transport
properties of the drugs by AC electric field. The commercial DEA instrument and the
customized B-cell yielded electrical properties of the drugs and their behavior and
performance in the drug delivery. Throughput in our study is based on an evaluation of a
closed system and measuring the drug content by UV Analysis. The DEA conductivity of
the aqueous solution drug at the end of test should be related to the efficacy of the drug
delivery. Basic transdermal patch material and transport properties can be determined.
Evaluation of a commercial patch will discover the fundamental properties needed for the
patch development.

xvii

PROTOCOL
Characterization and Transport Properties by Thermal– Bio-analytical Techniques
Synopsis


Characterization of commercial contraceptive transdermal patch, Orthoevera™



Study the transport properties and polarization of macro and micro molecular
drugs.

Terminology


All the significant terms are well defined



Defined all abbreviations

Scope


Qualitative and Quantitative measurements (DEA and UV)



Physical and electrical properties of the drugs are evaluated

Hazards


Care should be taken in handling specific drugs

Methods


Dielectric Analysis



Ultraviolet –Visible spectrometry



Differential Scanning Calorimetry



Thermalgravimetry



Lab wave 9000 Moisture Analyzer



Oven dry method

Summary of Methods


Instruments used in this study are briefly described

xviii



Test method principle

Calibration


Detailed instructions of calibration of the instrument are cited

Significance in Use


New approach for the Development of Transdermal Patches



Study of the Drug properties

Procedure


Standard protocols were performed for calibration of instruments



Describe successive steps for all the procedures

Interpretation of results


Directions for evaluating the results



List of all the tables



Specify significant figures

Research report


Detailed information required in reporting the results



Correlating the results

References


References to publications providing needed information



Keywords: Identify words, terms or phrases that best represent the technical
information reported

Conclusions


Summarize all collected data



Compare data from different methods

xix

CHAPTER I
INTRODUCTION
Transdermal drug delivery has made significant contribution to medical field,
standing as a better alternative to oral drugs and to the use of hypodermic injections too.
The use of topical medications to treat local infections on skin was in practice from many
years but the use of transdermal delivery system was becoming a well known practice
from a few decades. The scopolamine patch to treat motion sickness was first of its kind
to be formulated as a transdermal drug. Later the use of nicotine patches has become
popular to aid smoking cessation. Currently there are about 19 different transdermal
delivery systems available for hormones such as estradiol and testosterone and analgesics
such as fentanyl. Combination patches are available for contraception and hormone
replacement therapy.[1] Some of the most commonly used transdermal patches are as
follows: nicotine patch which releases nicotine for about 16 hours and prevent the
carving of cigarette by smokers, scopolamine patch which shows the effect for about 3
days, used to treat motion sickness and also in post operational nausea, fentanyl patch
which has its pain relieving effect for about 72 hrs and estrogen-progestin contraceptive
1

need to be taken only once a week rather than taking a pill every day.[2] This extended
release formulation provides better patient compliance.
Advantages
Transdermal systems are non-invasive and can be self-administered. Controlled
release of the medication is one of the advantages over other formulations like oral and
topical. It prevents gastrointestinal irritation which is more common effect seen with oral
formulations. This route of drug delivery bypasses the first pass effect of the liver which
is a potential advantage over oral formulation of drugs. It avoids multiple dosing of drugs
thus enhances patient compliance. They also improve patient compliance and the systems
are generally inexpensive.
Barrier
But one of the major drawbacks of this system is that skin being an effective
barrier; it is restricted only to the delivery of certain low molecular weight, lipophilic
drugs. The exploitation of transdermal drug delivery for the delivery of hydrophilic
drugs, peptides and macromolecules always remained as one of the great challenges. Skin
is composed of outer thick layer, stratum corneum which is about 10-20 µM thick. Below
this layer is epidermis which lacks blood vessels and measures about 50-100 µM. The
underlying layer beneath the epidermis is dermis which has blood capillaries suitable for
drug absorption. The major hindrance for the drug particles is stratum corneum,
composed of corneocyte cells cross-linked with keratin and intracellular spaces are filled
with a mixture of lipids arranged in bi-layers. Transport of drug particles through this
complex structure is a great ordeal that is faced. This necessitates the use of enhancers
2

that facilitate the transport of drug molecules by enhancing permeability of stratum
corneum.
Stages of transdermal drug development
The first generation transdermal drug delivery involved the delivery of lipophilic
and small molecules using traditional patch system. A typical scopolamine patch has an
outer backing layer which is impermeable, underneath of which a drug reservoir is
present. [1] Then a rate limiting membrane is present which controls the rate of drug
delivery from the reservoir, followed by an adhesive layer that sticks to the skin. A
protective layer is present which is removed just before using the patch. This generation
has been successful in delivering certain drugs.
The second generation advanced a little bit by using conventional chemical enhancers to
deliver other hydrophilic molecules. The enhancers used include Azone (1dodecylazacycloheptan-2-one) and SEPA (2-n-nonyl-1,3dioxolane).[2] But the use of
chemical enhancers is not very much successful in delivering hydrophilic and macro
molecules because these chemicals disrupted the inner skin layers. Other techniques like
iontophoresis and non-cavitational ultrasound have also been used. Iontophoresis increase
transdermal drug delivery by typically applying a continuous low-voltage current.
Iontophoresis does not affect the skin permeability but enhances drug transport by
providing an electrical driving force which makes it as an adjuvant method. [3,4]
Because Iontophoresis does not primarily change the skin barrier itself, it is mostly
applicable to small molecules that carry a charge and some macromolecules up to a few
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thousand Daltons, so this technique could not be an ideal technique for the delivery of
macromolecules and vaccines.
The third generation made use of cavitational ultrasound, Micro needles and
electroporation methods which are based on the principle of disrupting stratum corneum
on a nanometer scale. [5] Ultrasound generates cavitation, which is the formation,
oscillation and, in some cases, collapse of bubbles in an ultrasonic pressure field.[6] This
cavitation bubbles concentrate the energy of ultrasound and thereby enable targeted
effects at the site of bubble activity for the transdermal drug delivery.[7] Although
effective, applications of cavitational ultrasound may be limited by the need for a
sophisticated device that only increases skin permeability at the nanometer scale and
thereby may not be broadly applicable to macromolecules and vaccines. Electroporation
uses short, high-voltage pulses, a method to reversibly disrupt cell membranes for gene
transfection and other applications. It has shown to disrupt lipid bi-layer structures in the
skin.[8] During electroporation the electric field applied for milliseconds provides an
electrophoretic driving force. Diffusion through long-lived electropores can persist for up
to hours, such that transdermal transport can be increased by orders of magnitude for
small model drugs, peptides, vaccines and DNA [9]. Recently, electroporation was shown
to deliver a model peptide vaccine into the skin of mice to generate a strong cytotoxic T
lymphocyte response.[10] Although electroporation has been studied extensively in
animals, this approach to transdermal delivery has received limited attention in humans
because of the complexity of device design.
Limitation of diffusing large compounds through micron-scale disruptions, a long
time to diffuse through, longer treatment times, a very small amount of transported
4

molecules, and therapeutically insufficient amount of drug passing through in the
majority of applications leads us to develop novel thermal analytical techniques to
characterize drugs and drug delivery. The main goal of this study is to investigate various
variables and optimize the conditions such as length of treatment and low currents for
effective transdermal drug delivery of macromolecule e.g. insulin.

5
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CHAPTER II
INSTRUMENTATION
2.1. Dielectric Analysis
Dielectric Analysis (DEA) is a thermo analytical technique used to measure changes in
electrical properties of a sample, liquid or solid, as a function of temperature, time, and
frequency. The two fundamental electrical characteristics that DEA can measure for a
sample are Capacitance (High frequency permittivity e‘) or dielectric constant) and
Electrical conductivity (pS cm-1) Loss factor e‖) * applied frequency Hz) * a constant).
DEA measures three main parameters over a wide range of frequencies (e.g. 0.10 to
300,000 Hz): the loss factor (e”) which is related to the energy required to align dipoles
and move ions and is converted into the ionic conductivity (pS/cm). The permittivity (e’)
is another physical property and is related to the dipole content. Tan Delta is a ratio of
loss factor divided by the permittivity, e‖/e‘). An applied sinusoidal voltage on a sample
placed on a sensor creates an alternating electric field, inducing polarization of the
sample and followed by facilitate transport of the polarized drug through a biomembrane.

7

Figure 1: TAI Dielectric Analyzer 2970
Isothermal DEA procedure determines the polarization time of a sample and helps
in better understanding of the chemistry and molecular mobility that relates to the
structure of the drug. DEA is ultra-sensitive, and can measure conductivity from 103

pScm-1 and as high as 1012 pScm-1. DEA measures changes in dipole orientation and ion

mobility of the sample.
2.1.1. Instrument
Dielectric Analyzer (DEA) TA instrument (TAI) 2970 was used in this study.
Parameters such as temperature, sampling size, sample placement, calibration of the
sensor and temperature, are to be taken into consideration. The DEA can test various
forms of samples, i.e. gels, solutions, solids, powders, and thin films. Four types of
sensors exist for the TA Instruments DEA: parallel plate, single surface, sputter coated
and remote single surface. [2] Single surface gold ceramic inter-digitated electrodes are
used for the experiments. Measurements can be taken within a temperature range of -100
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ºC to 300 ºC and through a frequency range of 0.1 - 300k Hz. Dry nitrogen gas or air gas
purge at a flow rate of 50 mLmin-1 is used.
2.1.2. Calibration
New test procedures were applied that describes the temperature calibration
of Dielectric Analyzers with pharmaceuticals over the temperature range from 25°C to
250°C. This procedure uses pure Active Pharmacy Ingredients (APIs). This test method
can be used with a universal standard protocol for DEA. This new standard test method
can employ devices from a variety of commercial companies. Calibration is performed by
observing the melting transition temperature of standard Pharmaceutical materials within
the temperature range of interest.
Pharmaceutical test specimens (calibrants) of established melting temperatures are
evaluated in a closed system typically in a nitrogen atmosphere over a specific
temperature range. The test calibrants are evaluated by DEA using an interdigitated
electrode array (IDA) over a specific temperature range. At the transition temperature of
the test specimen, there is a change in permittivity which is recorded. These melt
transition temperatures of test specimens obtained from DEA data are compared directly
to the known literature melt transition temperatures.
The calibration materials used in this test development are: Acetanilide (Tmp, 113116°C) and Acetophenetidin (Tmp, 132-138°C).[7,8] These test protocols were
accomplished based on the Standard Test Method for temperature calibration of DEA and
ASTM E 2038 [1]. The preliminary R2 coefficient of correlation for known literature
transition temperature vs DEA Permittivity melt temperature for the calibrants was 0.98.
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These new pharmaceutical based test protocols, permit inter-laboratory comparison and
intralaboratory correlation of instrumental temperature scale data within the
pharmaceutical community, and will be implemented in our chemical pharmaceutical
research.

Figure 2: DEA curve of Acetanilide showing Log permittivity and Derivative of Log
permittivity transition temperature at 1 Hz frequency.
A summary of frequency used i.e. (single or set of 4 frequencies); permittivity and
Log permittivity transition temperature obtained from the DEA thermal curves of the
calibration materials are listed in: Acetanilide, table 1;
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Frequency (Hz)

Permittivity Transition
Temperature °C

Log Permittivity Transition
Temperature °C

1000 Hz

114

113

1Hz

116

113

10 Hz

115

113

100 Hz

114

114

1000 Hz

114

114

Average

115

113

Std Deviation

0.89

0.55

% Relative Error

0.77

0.48

Table 1: Acetanilide Tmp (113-116) °C; DEA Permittivity and Log Permittivity
Transition Temperature of single and set of frequencies.
2.1.3. Procedure
Dielectric analysis was performed using TA Instruments DEA 2970. For DEA, the
sample was placed on a single surface gold ceramic inter-digitated electrode and heated
to isothermal temperatures. The procedure includes ramp at 5oC min-1 to 37oC and held
isothermal for 45 minutes with a flow rate of 50 ml min-1 in nitrogen. Shedded snake
skin, a black snake skin (and pig skin were used in this study as a barrier for the transport
of insulin using an AC electric filed. DEA measures the electrical properties of the drugs
used in this study as a function of time, temperature, and frequency. Ionic conductivity
was then measured as a function of DEA variables to obtain permittivity [e‘], dielectric
loss [e‘‘] and loss tangent [tan delta=e‘‘/e‘]. Permittivity is proportional to the
capacitance and measures the number of dipoles. Loss factor is proportional to the
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conductance and represents the energy required to align dipoles and move ions by the
hopping model (Polaron theory). Ionic conductivity relates to the viscosity of the sample
because fluidity is identified by the ease with which ionic components can migrate
through the sample under the applied electric field.
2.2 Differential Scanning Calorimetry
Differential Scanning Calorimetry (DSC) is a thermoanalytical technique which
measures the difference in heat flow rate between a sample and reference as a function of
temperature. Both the sample and reference pans are maintained at nearly the same
temperature throughout the experiment. Differences in heat flow occur due to the heat
capacity of the sample which increases with temperature. The fundamental principle
underlying this technique is that, when the sample undergoes a physical transformation
such as phase transitions, less or more heat must flow to the sample depending on
whether the process is exothermic or endothermic. When less heat is required to raise the
sample temperature, there is a result of release of heat which results in exothermic
transitions. Crystallization and decomposition involves exothermic process. When more
heat flow is required to the sample to increase the temperature at the same rate as the
reference heat is absorbed resulting in endothermic transitions. Melting, glass transition,
and evaporation involve endothermic process.
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Figure 4: Mettler DSC 823e 20

Figure 3: TAI DSC 2920

DSC is widely used in the Pharmaceutical industries to characterize the drug
compounds in order to define processing parameters. The amorphous form of the drug is
a more efficient drug delivery material and is more bioavailable, but is less stable. It is
desirable to process the drug at temperatures below those at which crystallization can
occur. DSC also helps in providing changes in the water distribution correlated with the
water and solute interactions in a solvent.

Application of DSC with respect to

Pharmaceutical drugs and chemicals include melting temperature (Tm), Glass Transition
temperature (Tg), Glass transition size, crystallization temperature (Tc), crystallinity (Jg1

), and Polymorphic Transitions (Figure 5).
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Figure 5: Transitions in a DSC Curve
2.2.1 Instrument
The TAI DSC 2920 and Mettler DSC 823e were used to measure the heat flow
properties of pharmaceutical drugs as a function of time and temperature.

The

experimental parameters like sample size, environment, heating rate and pan type (open
pan, closed pan etc.). Solid Fat Index aluminum pans (Figure 6) are used in this study.
Sampling size can vary ranging from 2 mg to 15 mg, heating rates ranging from 1oC min1

to 100oC min-1. The performance of DSC is dependent on all these experimental

variables.
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Figure 6: Solid fat index (SFI) pans used for DSC; left- pan, right- lid
DSC operates over a temperature range of -100 to +300oC for pharmaceuticals. DSC
plots are obtained as the differential heating flow (in units of watts sec-1, joules sec-1 or
calories sec-1) with respect to temperature. Purge gas; typically Nitrogen (sensitivity) or
Helium (resolution) is used at a flow rate of 50 mL min-1 and liquid nitrogen cooling
when going below the room temperature.
2.2.2 Calibration
Calibration of the instrument is essential to have better consistency in results
obtained. DSC instrument calibration involves Differential Heat Flow, Temperature and
Baseline. Following the ASTM E968 method [4], Differential heat Flow is calibrated.
The characteristic temperatures and the enthalpy associated with a phase change of the
standard were compared to the literature values [7,8] (Figure 7). Heat flow calibration
should not change with heating rate.
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Figure 7: Differential Heat Flow calibration curve for Acetophenetidine showing
Tm and Tmp
Following the ASTM E967 protocol [5], the temperature of the instrument is
calibrated. High purity calibration standards such as Indium, Acetanilde [7] and
Acetophenitidine [8] are used for the calibration. DSC Baseline Slope is also calibrated.
2.2.3 Sampling
Sample shape, size and weights are to be considered during the packing of sample
in the aluminum pan for the DSC run. Sample should be as thin as possible, distributed
throughout the pan to have good thermal contact and cover as much of the pan bottom as
possible. The thin solid sample can be obtained by cut rather than crushed. A liquid
sample is placed in contact with the aluminum pan. A consistent DSC curve can be
obtained if there is a good thermal contact of sample with the base of the pan. The
experiment can be conducted with an open pan, covered pan or sealed pan and the pan
can be either a standard pan which has a flat base or a SFI pan that has crimped base and
the reference pan with similar configuration. Crimped pans always have the highest
16

sensitivity and resolution. The sample size can vary ranging from 2 mg to 15 mg and
should be weighed before and after the experiment to observe any mass loss upon
heating.
2.2.4 Procedure
Calibration of the instrument is the initial step and was performed by following the
ASTM standard protocol. Samples were weighed and placed in a SFI aluminum pans
with sampling size ranging from 2 mg to 15 mg. Open and closed pans were used in this
study depending on the nature of the sample e.g. solid or liquid. The samples were cooled
from 25 to -50°C and then heated to 120°C at 5˚Cmin-1 heating rate with nitrogen gas
purge of 50 mL min-1 for the study of liquids. Samples were heated to 30°C above the
melting point for solids to see the endothermic process and cooled to 50°C below the
melting point to see the exothermic crystallization process. A DSC scan usually provides
the following thermal properties: the Heat of Fusion ∆Hf), melting temperature (Tm), a
peak melt temperature (Tmp), Heat of Crystallization ∆Hc), crystallization temperature
(Tc), a peak crystallization temperature (Tcp), Heat of Vaporization ∆Hv), vaporization
temperature (Tv) and a peak vaporization temperature (Tvp).
2.3 Thermal Gravimetric Analysis (TGA)
Thermogravimetric analysis (TGA) or Thermogravimetry (TG) is a thermoanalytical
technique used to determine changes in weight of a sample as a function of temperature
or time (isothermal TG). A sample of exact weight is heated in a special instrument at a
given rate (˚Cmin-1) through a measured mass loss attributed to either of the following:
dehydration, solvent or solute desorption, a gaseous product formation from a reaction
e.g. loss of carbon dioxide from calcium carbonate with a residue of calcium oxide or
17

decomposition of the sample. Such analysis relies on a high degree of precision in three
measurements: weight, temperature, and temperature change.

Figure 8: Thermogravimetric Analyzer
The first derivative of the weight vs. temperature curve (DTG) highlights key
transitions or changes in the sample more definitively for enhanced interpretation. TG is
typically employed in research to characterize pharmaceuticals, chemicals, biological
entities or polymers. Combining TG with DSC measures endothermic processes a
function of temperature or time in a controlled atmosphere. The data obtained
differentiates endothermic and exothermic transitions with no associated weight loss
(e.g., melting and crystallization) and those that involve a weight loss (e.g., degradation).
2.3.1 Instrument
A TA Instruments Hi-Res TGA Model 2590 TG analyzer was used in these studies. It
consists of a high-precision balance with a pan loaded with the sample. Regular heating
of furnace and the sample holder up to 800°C in air for 10-15 minutes should be done to
keep them clean from organic residues. The sample is placed in a small electrically
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heated oven with a thermocouple to accurately measure the temperature. The atmosphere
may be purged with an inert gas to prevent oxidation or other undesired reactions.

2.3.2 Sampling and Procedure
The samples were prepared by placing one drop of material on to a pre-tared platinum
TG pan. The pan was placed onto the auto-loading mechanism of the TG analyzer and an
automated loading sequence was initiated. The sample is placed into a furnace which
heats the sample, while measuring the weight of the sample every 0.5 seconds. The TG
experimental conditions were: Ramp 10°C per minute to 500°C in nitrogen as purge gas
at a flow rate of 50 ml min⁻¹. 30-50mg of sample was used in each run. An inert
atmosphere, usually high purity dry nitrogen, is purged to prevent oxidation or other
undesired reactions. Then the data is analyzed using TA software.
TG rapidly measures changes in weight as a sample is heated and is eventually
vaporized. This can be used to create a water loss profile that can show the different
temperature ranges in which water and other components of a sample vaporize.
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CHAPTER III
CHARACTERIZATION AND PROPERTIES OF AN ORTHO
EVRA®TRANSDERMAL PATCH AND LIDOCAINE BY ISOTHERMAL &
SCANNING DEA
Abstract
An ideal delivery system must include a steady and prolonged therapeutically
effective drug concentration with or without minimum side effects. Unique modern
methods of drug delivery are turning to transdermal or transoral patches. A great deal of
research is being devoted to comprehend and smooth the progress of the growth of a
transdermal absorption scheme. The focus of this research is the monitoring of the
mobility of drugs and transport properties by Dielectric Analysis. DEA is used to track
the drug and drug transport as a function of temperature and frequency. Our first study
included characterizing a commercial contraceptive transdermal patch, Ortho Evra® by
thermal analytical techniques. The drugs in this product are norelgestromin and ethinyl
estradiol. DSC was used to detect any crystalline properties of the two drugs by their melt
properties. Having no melting temperatures due to the drugs and detecting a glass
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transition suggested that the drugs in the patches were amorphous. If they are amorphous
they are more bio-available. DSC also aided in identification of the polymeric adhesive,
the polymer backing and the drug properties. The isothermal DEA revealed critical
modulating frequencies at body temperature of 460 and 560 Hz for the two drugs.
Lidocaine is an anesthetic prominently used in dental procedures. DSC and DEA
properties of Lidocaine have led to a better understanding of transdermal and transoral
drug delivery. Lidocaine was evaluated by scanning DSC, isothermal and scanning DEA.
Scanning DSC results at the standard heating rate 10˚Cmin-1 were Tm 74˚C and Tmp
81˚C. At higher heating rates the melt temperatures were shifted to higher values tm 84˚C
and Tmp 89˚C. Heat of fusion was 138jg-1 and there appears no shift in the values with
higher heating rates. Scanning DEA determines the amorphous and crystalline forms of
the Lidocaine with respect to temperature. Testing of pure Lidocaine revealed that the
amorphous form is several order of magnitude more conducting that the crystalline
Lidocaine. Isothermal DEA determined the Critical frequency for Lidocaine transport
through the shedded snake skin at a frequency 70 to 100 Hz. This data is critical to the
development of an effective transoral patch.
Key words: Transdermal patch, Transoral patch, Dielectric Analysis, Critical Frequency,
Differential Scanning Calorimerty
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3.1

Introduction
An ideal delivery system must include a steady and a prolonged therapeutically

effective drug concentration with or without minimum side effects. A unique modern
method for drug transport is employing a transdermal patch. [1]The market for
transdermal drug delivery is over $3 Billion annual, just in the US, with this estimation
including only the traditional patch markets such as Lidocaine, Nicotine and Estradiol.
This type of patch avoids the chemically hostile gastrointestinal environment, has
reduced systemic side effects and sometimes has improved efficacy over other dosage
forms [4]. In addition since transdermal patches are user friendly, convenient, painless
and offer multi-day dosing, it is generally accepted that they offer improved patient
compliance [7].
Ortho Evra®, a commercial transdermal patch has 6.00 mg of norelgestromin and
0.75 mg of ethinyl estradiol as the API drugs. Molecularweight of norelgestromin is
327.47 and that of ethinylestradiol is 296.41. The patch is a thin, matrix-type consisting
of three layers: the backing layer, middle layer and the release liner.

The backing layer is a flexible film which helps in supporting and protects
the middle adhesive layer from the environment.
23

It has a low-density pigmented

polyethylene outer layer and a polyester inner layer. The middle layer contains the active
components; the two drugs norelgestromin and ethinylestradiol, and the polymer, Styrene
Butadiene Rubber (SBR) latex as a low molecular weight resins an inactive components.
The third layer is the release liner, which protects the adhesive layer (backing material)
during storage and is removed prior to the application of the patch. In this study we
determined the DSC and DEA properties of each drug.[5] DSC was used to detect any
crystalline drugs by their fusion properties. The research protocol was to determine the
Critical frequency of each drug in the patch on a Shedded Snake Skin at body
temperature as a function of ionic conductivity and time. DEA determined the ionic
conductivity of drugs in the patch since it was our hypothesis that the ionic conductivity
was directly related to drug delivery from a transdermal patch.
Lidocaine is a local anesthetic and antiarrhythmic drug. Lidocaine patches are
used to relieve the pain of post-herpetic neuralgia. It works by stopping nerves from
sending pain signals. Lidocaine is used topically to relieve itching, burning and pain from
skin inflammations, injected as a dental anesthetic or as a local anesthetic for minor
surgery. Lidocaine molecular weight is 234.34 da.

Lidocaine
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Bioavalability of Lidocaine when taken orally is 35% and 3% when used for
topical administration. Adverse drug reactions (ADR) of Lidocaine when used as a local
anesthetic and administered correctly have rare side effects. Most ADRs associated with
lidocaine for anesthesia relates to administration technique [13] and hence a great deal of
research is being devoted to comprehend and smooth the progress of the growth of a
transdermal absorption scheme. The continued focus of this research is the monitoring of
the mobility of drugs and transport properties by Dielectric Analysis. DEA is used to
track the drug as a function of temperature and frequency. DEA properties of Lidocaine
have led to a better understanding of transdermal and transoral drug delivery. Dielectric
relaxation processes [tan delta (loss factor/permittivity) vs. temperature] associated with
drug transport/activity in each patch were detected at body temperature. It appears that
the DETA properties are related to drug diffusion from the polymeric patch through the
bio-membrane to the gold ceramic interdigitated sensor.

3.2 Experimental Procedures
A TAI 2920 DSC employing a cool-heat-cool cyclic procedure at 10°Cmin-1 in
Nitrogen with closed-crimped aluminum pan and a typical 5 mg sample size. Lidocaine
melt temperature is 74-81oC. We also evaluated Ibuprofen with and without the shedded
snake skin. The commercial OrthoEvra®, the birth control patch was also evaluated to
verify the experimental conditions.
A TAI 2970 Dielectric Analyzer was used with a ramp of 5°Cmin-1 in Nitrogen
with single surface sensor interdigitated array gold ceramic electrodes were used to
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collected electrical properties of the Dentipatch®, USP Lidocaine, and USP Ibuprofen.
The TAI 2970 DEA was also set in the isothermal mode at 37oC employing a frequency
sweep from 0.10 to 10000 Hz for at least 50 minutes. The latter procedure was followed
for the Lidocaine crystalline solid by heating the sample through the melt to 100oC and
then cooled to room temperature. A second DEA run of the amorphous drug was initiated
and followed the same procedure as in the first run.
3.3 Results and Discussion
The DSC evaluation of the Ortho Evra® commercial patch revealed a low
temperature Tg at -29˚C. It is our interpretation that the Tg is due to a pressure sensitive
adhesive with a tackifier, typically used currently in commercial patches. [14] Usually the
polymer is Styrene Butadiene Rubber (SBR) latex as a low molecular weight resin. The
melting characteristics at higher temperatures were identified as the polymer backing
material of the commercial patch. The melting at 105 to 114˚C was repeated at 109 to
116˚C. This material was isolated and further identified by quench cooling the polymer in
liquid nitrogen, -120˚C, and further examined to find that the backing polymer was the
only crystalline entity in the patch. Therefore, the drug component was amorphous and
more bio-available, Figure 9
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Figure 9: DSC of OrthoEvra commercial patch

The scanning DEA produced a conductivity peak vs. temperature for the polymer
backing material at 93 to 95˚C. It is interpretated as the DEA melt temperature of low
density polyethylene which confirms the DSC results.

The peak conductivity

temperature was constant with all frequencies and therefore implies that it represents a
first order thermodynamic transition as a melt transition, i.e. melt of low density
polyethylene. (Figure 10)
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Figure 10: DEA conductivity peak vs. temperature

The Tan Delta vs Temperature plot yielded a bimodal critical peak response. (Figure 11)
The tan delta a Debye plot values, as a function of temperature and frequency at <100˚C
revealed a number of polarization processes due to the two drugs. It was assumed that
the lower four critical peak frequencies occurring at lower temperatures and the three
critical peak frequencies occurring at higher temperatures were taken both as a different
set of values. Our proof of concept was the plot of log peak frequency vs reciprocal
temperature (K-1) would have a statistical correlation coefficient of >0.95. We observed
for the lower temperature critical peaks the R2 was 0.98 (Figure 12) and R2 for the higher
temperature critical frequency peaks was 0.99 (Figure 13). These curve fits were then
used to determine a critical frequency at 37˚C by extrapolation for the two drugs. Based
on the functional group analysis and evaluation of the dielectric constant of the two drugs
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we assumed the lower peak frequency values were associated with ethinyl estradiol and
high peak frequencies were that of norelgestromin. The results are

460 Hz for ethinyl

estradiol and 562 Hz for norelgestromin. These critical frequency determinations were
confirmed by plotting Log ionic conductivity vs time and then determining the log
conductivity vs log frequency at 37˚C and at a time period of 20 min (Figure 14). The
deviation in this latter plot was determined and found to be within 10% the same values
for the first method to determine the critical frequencies for aiding drug delivery; both
methods gave critical frequencies of ca. 500 to 600 Hz to push the drugs from the patch
into skin. The isothermal DEA revealed a critical modulating frequency at body
temperature.

Figure 11: Tan Delta vs Temperature plot bimodal critical peak frequencies
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Figure 12: log peak frequency (Hz) vs reciprocal temperature (K-1)

Figure 13: log peak frequency (Hz) vs reciprocal temperature (K-1)
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Ortho Evara Transdermal patch
37˚C at 20min:
Critical frequency 500 Hz
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Figure 14: Log Conductivity (pScm¹) vs Log Frequency (Hz) Ortho Evra patch

Lidocaine, an analgesic, was also examined by DSC and DEA. The melt profile as
a function of heating rate is disclosed in Figure 15. The DSC results at the standard
heating rate 10 Cmin-1 were Tm 74˚C and the Tmp is 81˚C. However, when the heating
rate was increased to 75 or 100˚Cmin-1 the Tm was 84˚C and the Tmp was 89˚C for both
higher heating rates. The heat of fusion was 138 Jg-1 for the standard rate and 135, 144
Jg-1 for the higher rates. Only the Tm and Tmp increased but the heat of fusion appears to
be the same.
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Figure 15: DSC of Lidocaine with higher heating rates
The DEA curves of log ionic conductivity vs. temperature for Lidocaine or
Lidocaine.HCl were definitive in that the first run depicted a crystalline material, its solid
state with an initial ionic conductivity of 10-1 pScm-1 at 50oC. The melt properties as a
function of frequency were 105 to 106 pScm-1. The second run was clearly an amorphous
chemical with the initial ionic conductivity starting at 104 pScm-1 at 50oC and in the melt
106 pScm-1. The HCl salt of Lidocaine and the Lidocaine without the salt was observed to
have the same results.
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Figure: 16 Lidocaine Hcl Ionic Conductivity vs. Temperature
An alternative technique to determine the critical frequencies needed to
manipulate the drug and push it through a bio-membrane for DEA drug transport was
developed. First, plot log ionic conductivity vs. time and vary the frequency at a given
temperature. At a set time of 20 min. record the log ionic conductivity vs. log frequency.
Evaluate this last plot for significant change as an increase (the ionic drug is transporting
through the membrane) or decrease (the drug has completely transported through the
membrane) in the conductivity and note the critical frequency at the start of the variation.
This initial frequency variation is the ―critical frequency”. The critical frequency for
Lidocaine or Lidocaine.HCl was 70 to 100 Hz. This method of analysis for the critical
frequency was tested by evaluating a drug on a shed snake skin bio-membrane and
determining the effective drug through put by a calibrated UV analysis.
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Figure 17: Lidocaine Log ionic conductivity vs. time

Figure 18: Lidocaine Log conductivity vs log frequency
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From the plot of log ionic conductivity vs. log frequency for a crystalline
Lidocaine vs. an amorphous Lidociane, one observes clearly that the amorphous form is
more conducting than the crystalline form, which is a well known observation. (Figure16)

Figure 19: Log Conductivity vs. log frequency of amorphous and crystalline
form of Lidocaine
3.4 Conclusions
Having no melting temperatures due to the drugs, however a melting process due to the
backing polymer polyethylene and detecting a glass transition suggested that the drugs in
the patches were amorphous. If they are amorphous they are more bio-available. Drug
DEA properties proved appropriate in evaluating transdermal & oral patch drug delivery
as monitored by Ionic Conductivity. One can scan or ramp temperature employing DSC
and DEA to study the transdermal or oral patch for its components e.g. the polymeric
adhesive, the polymer backing material and the active ingredient, the drugs. Alternately
one can scan for the effect of the drugs by DEA at isothermal 37oC, that is, measure the
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ionic conductivity vs. temperature and frequency range (0.1 to 5000 Hz). Unique
dielectric properties of the Ortho Evra® patch have been determined. One can modulate
drug distribution [increase its transport through the shedded snake skin] at >600 Hz at
body temperature. The critical frequency for the commercial patch was based on the DEA
Tan Delta vs. Temperature and frequency plots using the Arrhenius Model. For
Lidocaine, the modulating drug distribution frequency is at 100 Hz based on the
isothermal DEA 37oC Conductivity vs. Temperature and Frequency. Transdermal and
Trans-oral patch drugs are amorphous and drug transport monitored by ionic conductivity
is enhanced over the crystalline drug as discovered when characterizing an Ortho Evra®
patch and Lidocaine on a model skin, shedded snake skins.
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CHAPTER IV
THERMAL AND BIO-ANALYTICAL CHARACTERIZATION OF AQUEOUS
DRUGS AID THE DEVELOPMENT OF DRUG DELIVERY IN ANIMAL
MODELS
Abstract
Transdermal drug delivery has many benefits over systemic oral therapies, in
which clinically sufficient quantities of the active pharmaceutical ingredient do not reach
the intended organ and/or use of the drugs result in serious side effects. However,
existing transdermal platforms are limited to drugs of small size, ionic nature and low
molecular weight. In the case of diffusion, treatment time is passively determined by the
typically slow diffusion process rather than the therapeutic need. An optimally-tuned
low-voltage applied AC electrical field has been found capable of inducing polarization
and delivering micro- and macromolecules through a biological membrane. In this study,
insulin, Diphenhydramine and Lidocaine gel were transported by AC electrokinetic‘s
through animal models, including pig skin and shedded snake skin at body temperature.
A factorial design was used to establish experimental parameters for the insulin solution
evaluating variables of voltage, frequency, time, temperature, drug dose, and membrane
thickness. Pre- and post-test conductivity measurements of the pig skin samples are taken
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as an indicator of drug permeation and changes in conductivity are correlated with
experimental variables to assess the relative importance of each variable to drug
transport. Dielectric Analysis was used to modulate the drugs delivery response measured
by a change in the log conductivity vs. log frequency curve at lower frequency of 500Hz
and a higher frequency of 1000 Hz for insulin at 37ºC. Proof of concept for the drug
transport was confirmed by examining a residue on the electrode by Ultra Violet
Spectroscopy. Lidocaine gel and Diphenhydramine as formulated drugs, in an aqueous
solution were also evaluated by the AC field to determine their transport performance. A
clear result of the experimental design for insulin was that the low frequency was
significant in enhanced drug delivery. Imposition of a low frequency of 500Hz aliened
dipoles and higher frequency aided the mobility of the drug ions into the bio-membranes.
Key words
Transdermal drug delivery, Dielectric Analysis, UV Spectroscopy, Lidocaine gel,
Diphenhydramine, insulin, AC electrokinetics, polarization

4.1 Introduction and Background
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Advances in biotechnology, particularly in recombinant protein technology, lead to a
great deal of attention to the therapeutic roles of peptides and proteins. Protein and
peptide drug delivery has been an area of intensive research because of their efficacy in
several disease conditions [1]. Most protein and peptide drugs are currently used as
parenteral formulations because of their poor oral bioavailability and they do not reach
the target organ either fast enough or in high concentrations when delivered via other
routes [3]. These drugs are usually recommended for chronic conditions, and the use of
injections on a daily basis during long-term treatment has obvious drawbacks [9]. Insulin
is the most important among the therapeutic proteins and peptides being explored. About
2 million American people are suffering from hyperglycemia which requires insulin for
the treatment. Exogenous insulin administration is basically a replacement therapy, when
administered subcutaneously yield a plasma profile which mimics the endogenously
secreted insulin in a normal individual. There is extensive research on several aspects of
the insulin delivery. In recent years, there has been a great deal of interest in the
exploitation of non-invasive routes for insulin therapy, and their development by the
pharmaceutical industry, including oral, nasal, buccal, pulmonary, transdermal, rectal,
and ocular drug delivery systems [16]. The transdermal patch delivery system presents
distinct advantages over systemic drug delivery in reducing the problem of
hyperinsulinemia[15, 16]. This new delivery system reduces the chance of micro and
macro angiopathy, infection and pain as well as improving patient compliance. Injection
dosing also has specific advantages as efficacy. The problems with injections include:
restricted fat deposition at the injection site, which leads to local hypertrophy, inability to
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load the syringe and administer it as well as the pain, cost and infections [21]. Therefore,
the transdermal dosing remains a better route for drug administration.
Compared to other means of drug delivery, the transdermal route offers
unique advantages: transdermal drug delivery is non-invasive; absorption is not affected
by food intake and is not subject to first-pass metabolism in the liver [11]. In addition,
active transdermal drug delivery systems allow precise control of drug dosing [10].
However the drug delivery is enhanced through modulation of an electric field (Dielectric
Transdermal process) used to drive drug transport [4]. All transdermal drug delivery
methods introduce therapeutic agents into the body through the skin. Drug transport can
either be passive, relying on drug diffusion across the skin, or actively driven by
application of an electric field [8]. The drug delivered, aided by an electric field, had
appropriate pharmacokinetics and pharmacodynamics, and the drug was stable in the
patch. Depending on the drug in the patch the time duration of delivery can be up to 1 to
7 days.
Electrically-assisted transdermal delivery is the facilitated transport of compounds
across the skin using an electromotive force. Depending on the nature of the applied
electric field, the molecule to be delivered and the barrier to be crossed, various
combinations of the driving forces such as iontophoresis, electrophoresis (EP),
electroosmosis (EO), dielectrophoresis (DEP), and others are used. Electrophoresis and
dielectrophoresis using alternating current (AC) and iontophoresis using a direct current
(DC) may be described as the electrically assisted movement of chemicals and molecules
through the membrane during the application of an electrical potential difference. These
techniques have been widely used in various medical fields, including topical and
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systemic drug delivery systems. In particular, the effectiveness of transdermal delivery
using electrokinetics for the administration of topical anesthesia and analgesia has been
widely reported reference. Another advantage of electrokinetic methods is the ease of
interpretation and characterization by Electrochemical Impedance Spectroscopy (EIS)
based sensors and detection methods.

EP and DEP in combination with EIS can

effectively trap, manipulate, separate and quantitatively detect particles ranging from
virus to large DNA strands, to bacteria and mammalian cells in micro fabricated devices.
Typically interdigitated electrodes and Microelectromechanical systems (MEMS)
technology are used because they are easy to fabricate, can generate strong electric fields
with a reasonable voltage, work optimally with micro scale particles, integrate seamlessly
with micro fluidics, and have analytical electric field solution available for modeling.
Electrochemically iontophoresis enhanced transdermal patches are often constructed
with one active or ―donor‖ electrode and one counter or ―acceptor‖ electrode which are
placed close to each other and directly against a tissue barrier (stratum corneum). The
delivered drug is attached to the donor electrode as a medication soaked sponge or gel.
In DC iontophoresis, a constant current or voltage is applied between the electrodes to
promote transport of a drug from the donor electrode to the acceptor electrode through
the tissue barrier, which is assumed to be a path of least resistance between the two
electrodes.

In practice this is usually not the case, often resulting in a very low

percentage efficiency of the drug delivery through the tissue barrier. In DC iontophoresis
the rate of drug delivery increases with the current and maintaining a high current (in the
1 mA range) by applying high DC voltage is desirable. However, these high currents
present risks to patients in the clinical setting (a current of 10mA can stop pace maker)

43

where the acceptable limit for a DC application is 10 µA. A number of adverse effects
have as a result of high applied voltages, including electric burns or erythema;[6] have
been reported for treatments involving DC iontophoresis. The application of DC-based
electrokinetics methods has been limited to a period of approximately 15 minutes. The
attempt was made to operate at higher frequencies (electrophoretic delivery at ~ 100 kHz)
where the high current threshold increases to 1 mA. However, this approach results in
uncomfortably long treatment times on the order of hours. Therefore, iontophoresis is
typically limited to low DC voltages in order to avoid potentially dangerous high
currents, resulting in a long treatment time (order of hours) required to achieve any
sizeable drug transport.

However, even for longer treatment times, the amount of

transported molecules is very small, and therapeutically insufficient in the majority of
applications. The main goal of this study is to investigate various variables and optimize
the conditions such as length of treatment and low currents for effective transdermal drug
delivery of macromolecule e.g. insulin.

4.2 Experimental Materials and Procedures
4.2.1 Biological tissue membranes and Drug selection
In this study selected biological tissue membranes- excised pig skin of 1-3mm
thickness and shedded snake skin of 1 mm thickness were used to investigate
electrokinetic drug transport. These skins serve as early stage models for transdermal
drug delivery in humans. Pig skin was stored in a plastic bag in the refrigerator at -10ºC
and shedded snake skin was stored in a plastic bag at 4ºC. The skins were excised and the
subcutaneous and fat tissues were removed. The excised skins were composed of stratum
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corneum, viable epidermis and upper epidermis. Stratus corneum, the outermost layer of
mammalian epidermis, acts as the main barrier for diffusion of substances through the
skin.
In this study, Insulin, Diphenhydramine, Lidocaine gel, Nimsulide and JCC 76
with different molecular weights and various polarities were selected as model drug
compounds. Insulin is a hormone that is central to regulate the energy and glucose
metabolism in the body. Insulin is a peptide hormone composed of 51 amino acids and
has a molecular weight of 5808 Da. The interior of insulin contains mostly non-polar
amino acid side chains, chains e.g. chain to chain bonding with cysteins which are
nonpolar and hydrophobic while the exterior contains mostly polar amino acid side.

Figure 20: Insulin primary structure
4.2.2 TA Instruments Dielectric Analyzer DEA 2970
Dielectric analysis was performed using TA Instruments DEA 2970. For
DEA, the sample was placed on a single surface gold ceramic inter-digitated electrode
and heated to isothermal temperatures. The procedure includes ramp at 5ºC min-1 to 37ºC
and held isothermal for 45 minutes with a flow rate of 50 ml min-1 in nitrogen. Shedded
snake skin, a black snake skin (figure 21) and pig skin (figure 22) were used in this study
as a barrier for the transport of insulin using an AC electric filed. DEA measures the
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electrical properties of the drugs used in this study as a function of time, temperature, and
frequency. Ionic conductivity was then measured as a function of DEA variables to
obtain permittivity [e‘], dielectric loss [e‘‘] and loss tangent [tan delta=e‘‘/e‘].
Permittivity is proportional to the capacitance and measures the number of dipoles. Loss
factor is proportional to the conductance and represents the energy required to align
dipoles and move ions by the hopping model (Polaron theory). Ionic conductivity relates
to the viscosity of the sample because fluidity is identified by the ease with which ionic
components can migrate through the sample under the applied electric field.

Figure 21: Shed snake skin

Figure 22: Pig skin on DEA sensor

4.2.3 B-Cell
The B-Cell (figure 23) was used for initial evaluation of drug transport through
biological tissue membranes - pig skin (insulin) and concluded with an experimental
design [4]. The selected biological tissue membranes were positioned with the use of
several adjusting springs at the bottom of the cell. Then the springs were pressed directly
against the ―bottom electrode‖ with the stratum corneum facing the electrode to provide a
realistic model of the 5-electrode setup being firmly placed directly against a skin. The
biological membranes were sealed properly to avoid cross contamination of the receptor
and the donor compartments. The receptor compartment is the bottom side of the
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membrane and the donor compartment is above the membrane containing the original
drug-containing substance and all the electrodes. The available diffusion area was
approximately 4 cm2. Approximately 50 mg samples of the drug-containing substance is
placed on the ―top electrode‖ from the above, with some amount of the substance
penetrating through the perforation and coming into contact with the biological tissue
membrane between the bottom Electrodes 4 and 5. However the majority of the drugcontaining substance remains in the perforation holes, between Electrodes 2 and 3
comprising the ―bottom electrode‖, and between the Electrode 1 and the plane of the ―top
electrode‖. A capping Electrode 1 covers the sample. All experiments were conducted at
250C.

Figure 23: B-Cell

Figure 24: Interdigitated electrodes

4.2.4 Experimental design and statistical analysis
A series of studies was performed to investigate variables which are important for
transdermal transport of drug and changes in the membrane conductivities as a function
of voltage amplitudes and frequencies, treatment time, and membrane thickness. This
type of factorial design identifies the most important parameters affecting drug transport
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such that the parameters can be optimized for effective transdermal drug transportation.
The resulting 3³*2 factorial design with two variables at two levels and three variables at
three levels incorporates a total of 54 studies.
4.2.5 UV Analysis
Drug delivery through the membranes was confirmed qualitatively and
quantitatively by UV spectroscopy. After completion of the drug delivery cycle the
sample in the receptor cell were collected and quantitatively analyzed by UV-Vis
spectrometry. The UV-Vis analysis at room temperature was performed and calibration
curves of known drug concentrations were developed (Insulin at 271.9nm). After each
experiment three aliquots were taken from each solution and each of these was scanned
three times. The average of these nine values was used to fit the calibration curve for the
peak UV absorbance measurements for the residue samples.
4.3 Results and Discussion
4.3.1 DSC and DEA Results
4.3.1.1 DSC
The heat of crystallization, heat of fusion and heat of vaporization of unbound water are
334, 334 and 2200 Jg-1, respectively. Understanding the role of the solvent (water) on the
solute drugs can be accomplished by evaluating and comparing the crystallization, fusion,
and vaporization heats of water in the solutions studied. Next, evaluating the
crystallization, fusion, and vaporization temperatures we further characterize the solute
drug in water. In table 2 and 3 the water analysis of each of the drugs in solutions/gel
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revealed that Insulin, Diphenhydramine, and Lidocaine gel crystallized 10˚C above pure
water. The melting temperatures were slightly lower than that of pure water and the peak
melting temperatures were slightly higher than the water for three drugs. The
vaporization properties of water were similar for insulin and Diphenhydramine, however
lidocaine gel was significantly difference with a lower amount of water associated to the
gel.
Relative
Tc

Tcp

ΔHc

Water

-34

-30

338

Insulin

-25

-19

Diphenhydramine

-25

Lidocaine gel

-21

Drug (liquid)

Relative
Tm

Tmp

ΔHf

101

-1.0

2.0

373

109

315

94

-3.6

3.1

335

100

-18

321

96

-2.1

4.2

345

102

-19

200

60

-4.6

1.4

177

53

ΔHc(%)

ΔHf (%)

Table 2: Heat of crystallization and heat of fusion by DSC of various drugs
Relative
Tv

Tvp

ΔHv

Water

99

105

1998

91

Insulin

102

112

2056

93

Diphenhydramine

123

131

1998

91

Lidocaine gel

109

111

1147

52

Drug (liquid)

ΔHv(%)

Table 3: Heat of vaporization by DSC of various drugs
A calibrated DSC yielded the melting temperature of Nimesulide at 148-150˚C,
heat of fusion 54 Jg-1, using the TAI DSC 2920 instrument. The literature value for the
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melting temperature is 143-144˚C. The crystallization temperature is 104-105˚C and heat
of crystallization is 46 Jg-1. The ratio of the heat of crystallization to that of heat of fusion
is the amount of the re-crystallized drug, i.e. 86% of the drug Nimesulide re-crystallized
and by difference 14% is an amorphous form. The melting point of JCC based on the
DSC results is 180-183˚C and the heat of fusion is 91 Jg-1 (see Figure 25 and 26).
There is no any recrystallization for JCC and hence it is in amorphous form.

Figure 25: DSC of Nimsulide
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Figure 26: DSC of JCC 76
4.3.1.2 DEA
DEA was used to monitor in vitro delivery of aqueous solutions and solid forms of drugs.
The Interdigitated single surface electrode was used to sense changes in the ionic
conductivity as a function of applied frequency at 37oC for 45 minutes. Pig skin was
employed as the animal model to test the drugs through put with frequency. Figure 27 is
an evaluation of pig skin without any drug applied but the effect of varying frequency
was measured. The ionic conductivity (pScm-1) is plotted against frequency with a linear
correlation from log frequency of -1 (10-1) to 105 Hz. The response fitted a linear curve fit
equation of
log conductivity = 0.668 log frequency + 4.92, R2 = 0.998 (a)
The insulin test on the electrode produced the next equation see Figure 28.
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log conductivity = 0.632 log frequency + 4.62, R2 = 0.996 (b)
The insulin on pig skin is described in Figure 29 to 31 and equation c and d where the
curve before the critical frequency of 1.0 Hz is log conductivity = 0.823 log frequency +
5.73, R2 = 0.995 (c ) and after the critical frequency log conductivity = 0.195 log
frequency + 7.29, R2 = 0.934 (d).
The interpretation of these curves and equations is that the insulin delivery was enhanced
as demonstrated by the slope or rate of charge transfer increase from 0.67 (pig skin only)
to 0.82 (insulin on the pig skin) or the ionic conductivity (related to the concentration of
the insulin) was enhanced 22%. This template of drug through put is the DEA measure of
effectiveness of this DEA technique. The slope or rate of ionic conductivity after the
critical frequency decreased to 0.19 and the curve is flat with minimum variation. This is
interpreted that the drug was passed through the membrane which will be evaluated by
UV analysis of the through put fluid described later in this chapter.
The next aqueous solution with a drug, was with diphenhydramine, and examined
the same manner. Figure 32 is the overall measure of log ionic conductivity vs. log
frequency from log frequency from 10-1 to 105 Hz, see Figure 33. Immediately seen is an
upward movement of the curve at 10 Hz and again at 100 Hz are noted as the critical
frequencies for this aqueous drug. The general equation curve fit was in Figure 33
Log conductivity = 0.549 log frequency + 5.85, R2 = 0.901 (e)
An evaluation of the curve by breaking down the range of response in this case to 10 -1 to
101 was in order (frequency range prior the critical frequency). This equation is (f) is
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Log conductivity = 0.780 log frequency + 5.80, R2 = 0.994 (f)
After the critical frequency of 1.0 Hz is viewed in Figure 35 and equation (g)
Log conductivity = 0.264 log frequency + 6.89, R2 = 0.323 (g)
This set of equations and curves implies that the pig skin slope 0.67 increased to 0.78 or a
16% ionic conductivity enhancement (or a 16% increase in drug through put, which will
be tested by UV analysis of the fluid beneath the pig skin. The slope after testing was
0.26 a decrease from 0.78 before the critical frequency. This is also interpreted as the
drug has passed through the membrane and is depleted from the membrane with a loss of
drug a lower ionic conductivity.

Mol. Wt.
Drug
(Da)

%

%
Throughput
by DEA
W/ Field (V)

Throughput
Control
W/O Field
(V=0)

Wavelength (nm)
UV peak for
Analysis

End point
Conductivity
(pScm-1)

22

2.4

290

3.7 x106

48

0.0

250

24 x106

72

3.2

270

26 x106

Nimesulide
308
(solid)
“JCC 76”
(solid)
Insulin
5808
(liquid)
Diphenhydra
255
81
17
214
48 x106
mine
(liquid)
Table: 4 % Through-put and end point conductivity by UV and Dielectric Analysis,
respectively.
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Pig skin

9
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R² = 0.9982
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2
1
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6
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Figure 27: DEA of pig skin

8

Insulin

7

Log Conductivity
pSecˉ¹

6
5
4
3

y = 0.6324x + 4.6147
R² = 0.9961

2
1
0
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2

3
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Figure 28: DEA of Insulin
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Insulin with Pig skin
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Figure 29: DEA of insulin behavior on pig skin

Insulin with pig skin before change
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Figure 30: DEA of Insulin behavior on pig skin prior to the critical frequency of 100 Hz
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Insulin with pig skin after change

Log Conductivity
pSecˉ¹

8.05
y = 0.1954x + 7.2929
R² = 0.9338

8
7.95
7.9
7.85
7.8
0

1

2

3

4

Log frequency (Hz)

Figure 31: DEA of Insulin after the critical frequency of 100 Hz
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Diphenhydramine
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Figure 32: DEA of Diphenhydramine as a function of frequency
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Diphenhydramine with pig skin
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Figure 33: DEA of Diphenhydramine on pig skin

Diphenhydramine before change
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Figure 34: DEA of Diphenhydramine on pig skin prior to the 10 Hz critical frequency
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Diphenhydramine after change
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Figure 35: DEA of Diphenhydramine on pig skin after critical frequency
4.3.2 B-Cell Results
4.3.2.1 Correlation Matrix
The correlation matrix of investigating variables and outcome measures showed
strong relationships |r|= 0.9 to 1.0) between Z, Z‘ and Z‖, indicating the strong
consistency and validity of the measurements. A moderately positive relationship (r=0.4)
is seen between Voltage and Z‖, based on the relationship between Z‖, which is
proportional to conductivity, and current as defined by Ohm‘s law. Analysis also revealed
a moderately negative (r = -0.49) relationship between pre- and post-test conductivity and
low frequency.
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K/pS cm-1
Time/sec
Z'/ohms
Z''/ohm
Z/ohm
Voltage/V
High Freq./Hz
Low Freq./Hz
Pre-test Z/ohm
Pre-test K/pS cm-1
Delta K pS cm-1

K

Time

Z'

Z''

Z

1.0
-0.05
-0.30
0.27
-0.30
-0.32
-0.09
-0.08
0.18
-0.18
0.78

1.0
-0.05
-0.01
-0.04
-0.02
0.02
0.03
-0.15
0.17
-0.19

1.0
-0.94
1.00
-0.26
-0.28
-0.17
0.29
-0.29
-0.18

1.0
-0.96
0.40
0.22
0.24
-0.30
0.30
0.17

1.0
-0.29
-0.27
-0.19
0.29
-0.29
-0.18

High Low Pre-Test Pre-Test
Voltage Freq. Freq.
Z
K
Delta K

1.0
0.03
0.03
N/A
N/A
N/A

1.0
-0.03
-0.08
0.09
-0.16

1.0
-0.61
0.63
-0.49

1.0
-1.00
0.76

1.0
-0.76

Table 5: Correlation matrix results
4.3.2.2 Factor Analysis
A factor analysis of the investigating variables and one outcome measure (K)
found two significant factors (p-value=0.79). The first factor contains the conductivity
and voltage variables and the second factor contains the time variable. The first factor
explains 22 percent of the variance in the outcome measures and the second factor
explains 20 percent of the variance, for a total of 42 percent of variance explained by the
two factors. This indicates that although the study has captured some of the major
driving factors of drug transport, other unique variables also contribute to variations in
outcomes.

Factor Loadings
Factor 1 Factor 2
K/pS cm-1
0.997
Time/sec
0.996
Voltage/V
-0.320
High Freq./Hz
Low Freq./Hz
Table 6: Factor analysis
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1.0

4.4 Analysis Results
Increase in conductivity was identified in five of the 54 studies; implying drug transport
is enhanced by the investigating variables in this study. The common features of the five
sets of optimal parameters were a voltage of 1V and a low frequency of 0.1Hz.( figure
36, 37) Time was not found to be a significant factor in transport, indicating the process
is not one of diffusion but is defined by the properties of the applied electric fields. Drug
permeation appears to be driven by voltage and low frequency, in combination with an
appropriate range of high frequencies.

Figure 36: Conductivity vs. Voltage

Figure 37: Conductivity change vs. Frequency

4.5 UV Analysis
Drug throughput into a saline solution below the pig skin membrane was
measured using a UV-Vis concentration analysis technique in which study sample
absorbances were fit to a linear calibration curve of standard samples. Peak absorbance
was measured at 271.9nm and three aliquots were scanned three times each for a total of
nine scans for each sample. Throughput ranged from 12 percent to 100 percent, with a
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mean of 57 percent based on a constant dose of 1mL (100uL) Insulin, with each unit of
Insulin equal to approximately 0.034mg for a total of 34mg in 1mL. Transport by weight
ranged from 4mg (12 percent of 100uL) to 34mg (100 percent of 100uL). Membrane
thickness ranged from 0.7mm to 1.8mm with a mean of 1.3mm and has a weak negative
correlation (r=-0.3) with throughput. The average standard deviation for the UV-Vis
scans was 0.016 and the average relative percent error of the absorbance readings was
1.8, with a range from 0.2 to 5.2.

Figure 38: Average distribution of Insulin frequency Vs. % through put
4.6 Conclusions
These results show the proposed series of successive AC fields was capable of
transporting clinically significant amounts up to 100uL of the macromolecular drug
Insulin (5,808 daltons) across membranes up to 1.8mm thick in as little as 400 seconds
given an appropriate range of high and low frequencies coupled with an AC voltage
signal of 1 to 4 Volts. Distance to cross the membrane was the most significant factor in
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determining throughput. Analysis of pre- and post-test conductivity pointed to five sets
of parameters with high conductivity change, which may be taken as an indication of
drug penetration into the membrane separate from drug transported through the
membrane to the solution below. In fact, the five studies with high conductivity changes
had relatively low throughput values, including the lowest value recorded of 12 percent
throughput. No localized heating or visible damage to membranes was observed.
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CHAPTER V
THERMAL ANALYSIS OF WATER AND MAGNESIUM HYDROXIDE
CONTENT IN COMMERCIAL PHARMACEUTICAL SUSPENSIONS OF MILK
OF MAGNESIA
Abstract
A standard protocol was developed to determine the water content by thermal
analysis of Milk of Magnesia (MoM). Differential Scanning Calorimetry (DSC) and
Thermalgravimetry (TG) were used in a novel manner for examining the physical
characteristics of the commercial pharmaceutical suspensions. Moisture analyzer and
oven-dry methods validates the proposed protocol.
MoM consists primarily of water and magnesium hydroxide (Mg(OH)2).
Experimental design of the thermal analysis parameters were considered including
sample size, flowing atmosphere, sample pan and heating rate for both DSC and TG. The
results established the optimum conditions for minimizing heat and mass transfer effect.
Sample sizes used were: (5-15 mg) for DSC and (30-50 mg) for TG. DSC analysis used
crimped crucibles with a pinhole, which allowed maximum resolution and gave well
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defined mass (water) loss. TG analysis used a heating rate of 10oCmin-1 in an atmosphere
of nitrogen.
The heat of crystallization, heat of fusion and heat of vaporization of unbound
water are 334, 334 and 2257 Jg-1, respectively (3). The DSC average water content of
(MoM) was 80%w for name brand and 89.5%w for generic brand, based on the relative
crystallization, melting and vaporization heats (Jg-1) of distilled water to recently
purchased (2011) MoM samples. The TG showed a two step process, loosing water at 80135oC for unbound water and bound water (MgO.H2O) at 376-404oC, yielding a total
average water loss of 91.9% for name brand and 90.7% for generic brand by mass. The
difference between the high temperature TG and the lower temperature DSC can be
attributed for the decomposition of magnesium hydroxide or MgO.H2O. Therefore in
performing this new approach to water analysis heating to a high temperature
decomposed the magnesium hydroxide residue. It is our considered opinion that the DSC
method is more accurate than the TG protocol for unbound water.
Key Words: Milk of Magnesia (MoM), Differential Scanning Calorimetry (DSC),
Thermal Gravimerty (TG), Unbound water and Bound water
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5.1 Introduction
In general, water can be organized by phases of matter: liquid, solid and gas. The
liquid phase is the most common among all the water phases on the surface of the earth
and this phase is noted as ―water‖. The solid phase of water is a physically hard structure,
which is commonly known as ice. The gas phase of water is recognized as vapor or the
―vapor phase‖ of water. The physical chemistry of water is denoted as one molecule of
water where two hydrogen atoms are covalently bonded to a single oxygen atom (2).
Liquid water has no taste or odor and at normal atmospheric temperature and pressure
water is colorless, however it can have a very light blue hue. Ice is colorless, water vapor
or steam cannot be seen as a gas. At standard conditions, 25˚C and pressure 1atm water
is a liquid. The water molecule has a net positive charge on the hydrogen atoms and a net
negative charge on the oxygen atom. The net result is that each water molecule has a
dipole moment. Water is a polar liquid that can form a hydronium ion (H3O+) and is
interactive with hydroxide ion (OH-).
2 H2O (l)

H3O+ (aq) + OH− (aq)

The heat of vaporization, (ΔHv), is the energy to change a given quantity of water
into its gas phase at the standard temperature and pressure. Heat of vaporization for water
is 2257 Jg-1. The heat of fusion (ΔHf) is the result of the change in the phase of water
from solid to liquid which occurs at the melting temperature (Tm)). Heat of fusion for
water is 334 Jg-1. The heat of crystallization (ΔHc) is the result of the change in the phase
of water from liquid to a solid which occurs at the crystallization temperature (Tc)). Heat
of crystallization for water is 334 Jg-1[3].
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The following is a summary from W.J. Sichina paper ―Characterization of Water
of Hydration of Pharmaceuticals Using the DSC‖. He developed a test to characterize the
properties associated with the waters in a pharmaceutical material. The method includes
automated sample pan puncturing accessory for the study of free and bound waters in
pharmaceuticals. An additional protocol for determining hydrated pharmaceuticals
materials is DSC. Sichina‘s DSC protocol includes a thermal program: heat from room
temperature at 10˚Cmin-1, sample mass approximately 4 mg, sample pan 30 µl aluminum
pan with a hole, and purge gas nitrogen [2].
Milk of Magnesia is a suspension of magnesium hydroxide Mg(OH)2 in water. It
is widely used as an antacid to neutralize stomach acid and laxatives. Low solubility of
Mg(OH)2

in water makes it a weak base and considered as a strong electrolyte. The

United States Pharmacopeia states that single strength Milk of Magnesia should contain
not less than 90.0 % and not more than 115.0% of the labeled amount of 80 mg of
Mg(OH)2mL-1.

It is commercially produced by the precipitation of magnesium

hydroxide paste from seawater. The paste can have varying degrees of viscosity, which
determines whether a suspending agent is required or not.

Water, whose melting

/crystallization temperature and enthalpy are not significantly different from those of
normal (bulk) water, is called free water or freezing water or unbound water. Those
water species exhibiting large differences in transition enthalpies and temperatures, or
those for which no phase transition can be observed calorimetrically are referred to as
bound water.
The purpose of these experiments is to find the best analytical method to
determine bound, unbound water and water activity. Oven-dry and moisture analyzer
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methods are traditional methods, which are used in this experiment as controls. They are
used to determine the total water lost from the test samples. Since both traditional
methods can only determine the total amount of water lost, these methods cannot be used
to determine bound, unbound water and water activity.
TG rapidly measures changes in mass as a sample is heated and is eventually
vaporized. This can be used to create a water loss profile that can show the different
temperature ranges in which water and other components of a sample vaporize. DSC
analyzes the phase changes in matter and can also be used to determine a water loss
profile. Both methods can be used to determine the amounts of bound and unbound water
and from which can be used to determine the total amount of water lost in a sample. This
will be compared to the traditional controls to determine if the novel methods can be
accurately used to determine bound, unbound, and total water in a sample of milk of
magnesia.
5.2 Experimental Methods
The laxatives used in the study were a brand name milk of magnesia and a generic brand
milk of magnesia. Each product was tested for water content using two conventional
methods: 110°C oven, and moisture analyzer and two novel methods: Differential
Scanning Calorimetry and Thermalgravimetry.
5.2.1 110°C Oven Method
This method used small aluminum pans, a vacuum oven set to 110°C, and a desiccator.
First, the aluminum pans were analytically weighed and recorded to 3 decimal places.
Next, two samples of each product were analytically weighed from 1.5-2.0 grams onto
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separate pre-weighed pans to 3 decimal places and recorded. Then the pans were placed
into the vacuum oven. The oven used was a Fisher Scientific Isotemp® vacuum oven
model 282A (figure 39). Pans and samples were left in the oven for 3 hours at 15 kPa
vacuum. After 3 hours, the pans were removed from the oven and immediately placed
into desiccator under vacuum for 1 hour. After one hour, the pans were removed from the
desiccators and were analytically weighed and recorded to 3 decimal places.

Figure 39: Fisher Scientific Isotemp® 282A
5.2.2 Moisture Analyzer Method
Samples of each product were analyzed for moisture content using the Lab wave 9000
Moisture Analyzer (figure 40). The moisture analyzer uses an analytical balance inside of
a microwave oven (figure 41), which dries the sample, while recording a change in mass.
At the end of the test the percent moisture of the sample is automatically calculated. First,
two absorbent pads are placed on the analytical balance inside the moisture analyzer and
the balance is tared. Next, 1.0-1.5 grams of sample is placed in between the absorbent
pads. Then the moisture analyzer is activated, using 80% power. The sequence is
completed when the moisture analyzer no longer records a change in mass. The
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instrument then displays the percent moisture, percent solids, and the amount of time it
took to complete the analysis.

Figure 40: Lab wave 9000

Figure 41: Inside

5.2.3 Thermogravimetry Method (TG)
A TA Instruments Hi-Res Thermalgravimetric Analyzer Model 2950 (figure 42) was
used to measure bound and unbound water in milk of magnesia samples. The samples
were prepared by placing one drop of material on to a pre-tared platinum TG pan. The
pan was placed onto the auto-loading mechanism of the TG analyzer and an automated
loading sequence was initiated. The sample is placed into a furnace which heats the
sample, while measuring the mass of the sample every 0.5 second. The TG experimental
conditions were: Ramp 10°C per minute to 500°C in nitrogen. 30-50 mg of sample was
used in each run.
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Figure 42: Thermalgravimetric Analyzer Model 2950

5.2.4 Differential Scanning Calorimetry Method (DSC)
The Mettler DSC 823e 20 instrument (figure 43) was used to measure the heat flow
properties of the milk of magnesia samples which involve exothermic or endothermic
processes as a function of time and temperature. Samples were placed in solid fat index
(SFI) aluminum pans with sampling size ranging from 5 mg to 15 mg, covered with a lid
and were sealed. The samples were cooled from 25 to -50°C and then heated to 120°C at
5˚Cmin-1 heating rate with nitrogen gas purge of 50 mL.min-1. Closed pans were used in
this study. The DSC scan provided data of the following thermal properties: Heat of
fusion

∆Hf), melting temperature (Tm), peak melt temperature (Tmp), heat of

crystallization ∆Hc), crystallization temperature (Tc), peak crystallization temperature
(Tcp), heat of vaporization ∆Hv), vaporization temperature(Tv) and peak vaporization
temperature(Tvp).
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Figure 43: Mettler Toledo DSC

5.3 Results and Discussion
The results of % water from the 110°C pan method are shown in table 7:

Source drug suspension

Sample Water

Milk of Magnesia (Name Brand)

1

91.8% 91.8%

2

91.7%

Milk of Magnesia (Generic Brand) 1

Average

90.6% 90.%6

2

SDEV
0.0

0.1

90.7%

Table 7: Results of % water from pan method
The results were obtained by subtracting the mass of the pan and sample after testing,
from the initial mass of the pan. The difference was the amount of solids left in the pan.
From there, the mass of the material left in the pan was subtracted from the initial mass of
the sample. The data shows that the amount of water in the commercial brand of milk of
magnesia to be 91.8% and the generic brand of milk of magnesia was 90.6%. The
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moisture analyzer results were virtually identical to the results obtained from the 110° C
pan method as seen in Table 8.
Total Water (Oven)* Total Water* (Analyzer)
MoM (Name Brand)

91.8%

91.9%

MoM (Generic Brand) 90.6%

90.8%

*Average values
Table 8: Comparison of two conventional methods for water content in milk of magnesia
TG data was analyzed using Universal Analysis 2000, by TA Instruments, version 4.4A.
The data was plotted and analyzed using the first derivative of the percent (%) mass loss
versus temperature in °C. From there, each peak was identified and the percent material
loss was calculated. Also identified were the initial and end points at which mass loss
began and ended. All remaining material in the sample was calculated as percent residue.
The results are shown in figures 44 and 45.
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Derivative Mass Change %/°C

Mass/°C

Temperature/°C

Mass/°C

Derivative Mass Change %/°C

Figure 44 : TG analysis for name brand

Temperature/°C

Figure 45: TG analysis for generic brand
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In comparison to the conventional methods, TG analysis showed both bound and
unbound water. Water vaporization results are shown in table 9. The unbound water
vaporized between 80°C and 119°C in the name brand MoM. The unbound water in
generic brand MoM vaporized between 91° and 135°C. The bound water in the name
brand MoM vaporized between 376° and 398°C and between 374° and 404°C in the
generic brand MoM.

Unbound Water Bound Water Total Water
MoM (Name Brand)

88.0%

2.2%

90.2%

MoM (Generic Brand) 88.3%

2.4%

90.7%

Table 9: % of unbound water and bound water for test samples by TG
DSC results are summarized in the Figures 46, 47 and 48 as well as tables 10 and
11. The free water concentrations were determined based on the cool and heat DSC
curves. The heat of crystallization, ΔHc (from the cooling curve) and the heat of fusion,
ΔHf (heating curve after crystallization) were calculated for pure water and the
commercial suspensions of milk of magnesia produced by a name brand and a generic
pharmaceutical contract packager. The free or unbound water are the focus of this study
and by difference the amount of water relative to the ―pure‖ water. Assuming a two
component suspension of water and magnesium hydroxide (Mg(OH)2 suspended in the
water), various samplings of the commercial suspensions were evaluated by the DSC
curves. The average, standard deviation and percent relative error were calculated from
the ΔHc and ΔHf measured and are reported in table 10. The standard deviation was ± 17
to ± 22 and the % relative error was 5.3 to 7.6% for the heat measurements. The heat of
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vaporization was recorded during the DSC run but due to baseline variations and
sampling techniques were not used for the calculation of the water content.

Figure 46: DSC analysis for distilled water

Figure 47: DSC analysis for name brand MoM
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Figure 48: DSC Analysis of Generic brand

%
Average

Standard

ΔHc/Jg-1

deviation/±

Drug (liquid)

%
Average

Standard

ΔHf/Jg-1

deviation/±

Relative

Relative

error

error

Distilled water

338

19

5.5

373

20

5.3

Milk of Magnesia (Name Brand)

276

17

6.1

291

18

6.2

Milk of Magnesia (Generic Brand)

312

18

5.4

326

22

7.6

*All values Hc and Hf are based on three samplings
Table 10: Average, standard deviation and % relative error of ΔHc and ΔHf
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Average
Tc

Tcp

ΔHc

Relative

Tm

Tmp

ΔHf

Relative

of ΔHc

°C

°C

Jg-1

ΔHc%

°C

°C

Jg-1

ΔHf%

and

Drug (liquid)
ΔHf
Distilled water

-18

-14

338

100

Milk of Magnesia (Name Brand)

-17

-13

276

82

0

3.0

373

100

100

2.0

291

78

80

2.0

326

87

89.5

1.2
Milk of Magnesia (Generic Brand)

-17

-12

312

92
1.3

Table 11: Relative ΔHc , ΔHf and average of ΔHc and ΔHf
The final summary of the DSC analysis includes: the temperature profile of the free or
unbound water, its water content relative to the ΔHf and ΔHc and the average result of the
water by both analytical techniques, see table 12. The Milk of Magnesia, name brand and
generic brand was 80.0% and 89.5%, respectively by DSC. Therefore, there appears to be
a 10% variation between the two MoM commercial samples.
Oven

Moisture

Source Suspension

Mettler

Viscocity*

DSC

mPa∙s

TG
110˚C

Analyzer

91.8%

91.9%

90.2%

80.0%

1585

90.6%

90.8%

90.7%

89.%

2980

Milk of magnesia (Name
brand)
Milk

of

Magnesia(Generic Brand)
*Brookfield DV II+ Viscometer (#3 RVT spindle at 20rpm)
Table 12: Percent of water content from all the techniques and viscosity for test samples
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An overview of the water content by four analytical techniques is reported in table 12.
The water content for the Oven Test at 110˚C, the Moisture analyzer, TG and DSC for:
Name Brand was 91.8, 91.9, 90.2 and 80.0%w, respectively.
Generic Brand was of 90.6. 90.8, 90.7 and 89.5%w, respectively
The differences between the brand and generic were the same for the oven, moisture
analyzer and TG methods. There was a repeatable difference based on the DSC analysis
of 10% more water in the generic sample. Further, there was a sizable viscosity
difference of 88% between the brand and generic. The generic had more water and a
higher viscosity. The latter may be due to the additional additives denoted by 20 mg
calcium and 2 mg sodium in the generic product. The calculation of water activity was
developed to account for the intensity with which water associates with various nonaqueous constituents, e.g. MOM. It is a measure of the energy status of the water in a
system (10, 11, and 12). It is defined as the vapor pressure of a liquid divided by that of
pure water at the same temperature, yielding a value of one or 100%. It is our
interpretation that the difference noted in the DSC analysis is due to water activity and
can be uniquely evaluated by DSC.
5.4 Conclusions

The conventional methods of water analysis, oven and moisture analyzer provided total
water. TG is used to determine the bound and unbound water in MoM. DSC uniquely
discovered 10% more water in the generic probably due to water activity. The differences
in alkali metal content can be associated with the DSC water activity or may be related to
the enhanced viscosity of the generic brand.
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CHAPTER VI
AC ELECTROKINETIC PLATFORM FOR IONTOPHORETIC
TRANSDERMAL DRUG DELIVERY
Abstract
Iontophoretic and electroporation transdermal delivery modes of ionic drugs have been
utilized in a number of clinical and biomedical devices. However, applications of these
methods have been found challenging for the delivery of many non polar and high
molecular weight clinically important drugs. The main goal of the present study is to
investigate whether transdermal transport of non polar macromolecular drugs such as
insulin and terbinafine can be safely enhanced as a result of their polarization and
activation by AC electrokinetic forces. An in vitro delivery system was developed to
simulate a clinical application, where transdermal non invasive delivery of medication
through a biological membrane is motivated by a combination of AC electrokinetic and
AC iontophoresis protocols generated on a device located external to the membrane. The
developed method resulted in an average transdermal delivery of 57% of insulin and 39%
of terbinafine during several minutes long delivery cycle, which is at least an order of
magnitude improvement over the results reported for these drugs in the literature for
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various passive and active transdermal delivery protocols. For the proposed drug delivery
model quantification of the amounts of transported drugs and their relationship to
experimental parameters, such as AC voltage amplitude and frequency, treatment time,
and membrane thickness were investigated. Experimental results validated a
computational model simulating the effects of major electrokinetic forces on drug particle
in non uniform AC electric field. The presented transdermal approach overcomes many
limitations of existing drug delivery technologies, providing efficient, regulated,
localized, non invasive and safe delivery method for high molecular weight non polar
macromolecules such as insulin.
Key words
Electrokinetics, Iontophoresis, Impedance, Insulin, Terbinafine, Transdermal
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6.1 Introduction
Over the past decade non invasive transdermal drug delivery has become increasingly
common. Transdermal drug delivery offers many benefits over oral, IV and injection
therapies, in which procedures often result in adverse clinical side effects, and/or
clinically sufficient quantities of the active ingredient do not reach the intended organ
either fast enough or in high enough concentrations. That typically occurs because of the
partial medication degradation when passing through various physiological environments
(e.g. low pH values in the stomach), slow or incomplete absorption, or adverse affect on
healthy organs and tissues. Transdermal procedures provide improved bioavailability and
pharmokinetics, offering localized non invasive treatment, prolonged controlled release,
and increased patient compliance. However, only a limited number of drug candidates
have been successfully developed into suitable transdermal formulations because of the
formidable dermal barriers such as stratum corneum outer layer of the skin. Further
advancements in transdermal methods are required, especially for delivery of high
molecular weight non ionic drugs [1]. Most of contemporary transdermal products are
based on passive diffusion of a drug through skin over time. More recently, ―active‖
iontophoresis drug delivery methods that may transfer a drug at a controlled rate have
been developed and commercialized as transdermal patches [1-9]. Transdermal
iontophoresis is a technology that enhances drug transport across the skin barrier with the
assistance of an electric field. The mechanisms of transdermal iontophoresis include
electrophoresis (EP) [10-12], electroosmosis (EO) [13, 14] and electroporation [15, 16].
Direct current (DC) iontophoresis is the most common type. Electroporation and
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iontophoresis skin treatment have been shown to be effective through induced
disorganization of lipid bylayers of stratum corneum and increase in skin hydration [5-7].
High current intensity (in case of electroporation) or extensive treatment times (in
case of DC iontophoresis) can potentially lead to electrochemical burns, pain, and skin
irritation [5, 6]. It has been suggested that AC iontophoresis can eliminate these negative
side effects [17, 18]. Although high amplitude AC field applied in frequencies exceeding
10 Hz may provide less flux enhancement than DC field, significant flux enhancement
has been observed during AC iontophoresis at constant current or constant voltage [1721]. It has been shown that the AC electric field reduces skin electrical resistance by the
mechanism of electroporation similar to that which occurs during DC. This
electroporation effect has been found to dramatically increase with the AC voltage
amplitude [20]. The flux enhancements due to EP and EO have been shown to be
dependent on the AC voltage and AC frequency range [18].
Iontophoretic methods, however, were shown to be only of a very limited
efficiency in transdermal transport of many clinically important non polar and high
molecular weight drugs (such as insulin and terbinafine) [2]. Even for longer treatment
times transdermal delivery of conventional insulin in humans has been largely
unsuccessful presumably due to its weak ionization and partial polymerization, although
a delivery of modified, strongly ionized monomeric form of insulin was successful in
animals [22]. Inducing a temporary polarization on otherwise non polar macromolecules
may result in better overall compliance with iontophoretic transdermal transport.
Recent years have witnessed significant advances in the field of electrokinetic
manipulation of various biological species. Electrokinetic forces, such as EP EO, and
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dielectrophoresis (DEP) have been widely used for manipulation, detection and
separation of nano- and microparticles, such as proteins, bacteria, DNA, and blood cells
[23-27]. Magnitude of forces can range widely, depending on particle size, position away
from electrode and characteristic dimension of the electrode. A useful approach to
manipulate particles at the microscale is to use electric fields to apply long range EP
forces to charged particles, or induce dipoles and separate particles using a relatively
short-range DEP. Electrokinetics has shown to be ideal for the manipulation of particles
with sizes down to 20 nm, when small electrode channels (100 nm) and high voltages
(~10 V) are utilized [24]. Electric fields work optimally with microscale particles and
MEMS devices, integrating seamlessly with microfluidics and electrochemical sensors
[27].
Relatively few systematic studies of AC motivated drug delivery methods in
clinical settings, in particular those of higher molecular weight drugs, have been
performed [28-30]. AC electrokinetics with its ability to vary effects of different forces
on a particle may potentially become a highly effective method of drug delivery through
biological membranes. However, the efficiency of drug delivery has to be optimized
while making sure that currents through tissue membranes are kept low, treatment times
are short, and the risk of localized electrical heating and other potential side effects are
controlled. The main goal of this study was to investigate whether transdermal transport
of two macromolecular drugs — insulin and terbinafine could be safely enhanced using
the principles of AC electrokinetics.
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6.2 Materials and methods
6.2.1 Materials
Terbinafine hydrochloride (Lamisil) is a synthetic non polar antifungal drug with a
molecular weight of 291.43 g/mol and molecular size of ~0.78 nm. For terbinafine
delivery studies Lamisil cream formulation (1% terbinafine, or 10 g/L), widely available
over the counter, was selected. Insulin is a high molecular weight (5808 Da or ~9500
g/mol) peptide hormone with the interior composed of non polar amino acid side chains,
while the exterior contains polar amino acid side chains. The molecular dipole moment of
a monomer insulin molecule is a fairly sizeable 72 D at 25 °C [31]. The molecule has a
size of ~2.8 nm but larger aggregates may grow in time in aqueous solutions. For
transdermal insulin delivery studies, Humalog® N (Eli Lilly, Indianapolis, IN) was
chosen as a standard rapid acting insulin formulation in wide clinical use. Humalog® N
is an isophane suspension of human insulin in a 10 mL vial of 1000 units, or
approximately 4.17 g/L. Viscosity (0.001 Pa s), thermal conductivity (0.6 J/m sec K),
permittivity (80) and electrical conductivity 10 μSm/m) of background mediawere taken
to be approximately equal to those of water at roomtemperature. For insulin and
terbinafine the values for permittivity (55 and 20, respectively) and conductivity (500
μSm/m and 100 μSm/m, respectively) were estimated from the impedance measurements,
in agreement with the literature data on these drugs and their amino acid components
[31]. Insulin and terbinafine conductivity values were confirmed by the measurements of
the particle seizes and the zeta potentials (−20.1±1.3 mV and −6.6± 1 mV, respectively)
at physiological pH 7.4 (Brookhaven Zeta PALS,Brookhaven Instruments, Holtsville,
NY).
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Excised pig skin and cow hoof were selected to serve as models of human skin
and nail tissues, respectively [32, 33]. Animal tissues are readily obtainable in sufficient
quantities to allow conducting properly controlled and reproducible multiple experiments.
Pig skin samples with thickness ranging from 0.1 cm to 0.2 cm were obtained from the
breast region of adult Yucatan pigs because of the lower density of hair follicles in this
area, and were stored in sealed plastic bags in a refrigerator at −80 °C before use. The
surfaces of the skins were cleansed with a mild skin-cleaning gel normally used for
bioelectrical measurements and residual hair was removed with clippers. The epidermis
and upper dermis were removed with a dermatome. 0.1 cm thick (±5%) cow hoofs were
washed in the donor compartment buffer, dried, and stored in desiccator until use. The
surface areas of both membranes were cut to approximately 2 cm×2 cm.
The membranes were mounted between two side-by-side diffusion chambers
(diffusion surface area around 4 cm2 and cell volume of 4 mL) with the stratum corneum
side facing the donor chamber. The biological membranes were sealed properly to avoid
cross contamination of the ―receiver‖ and the ―donor‖ chambers. Approximately 500 μg
samples of Lamisil cream or 500 μL of Humalog® solution were placed in the donor
chamber. The receiver chamber was filled with phosphate buffered saline (PBS),
containing 1.5% bovine serum albumin (BSA) (pH 7.4) or absorbent cloth was used to
capture transported substance and overnight. The pH of the receiver solution was checked
in a few occasions and was found to be essentially the same during the experiments. The
receiver chamber was thermoregulated at 32±1 °C (skin temperature in vivo) in heated
bath system (Lauda, Lauda-Königshofen, Germany). Both donor and receiver chamber
solutions were replaced after each experiment. The experimental system composed of the
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donor and the receiver chambers, the membranes, and the iontophoretic electrodes, were
housed in a rectangular (2 cm×2 cm×2 cm) polyamide cube designed and manufactured
in-house (Figure 49A). The system employed three separate voltage and current carrying
electrodes — a counter electrode prepared out of a 0.1 cm thick stainless steel 316 metal
film (Electrode 1), and two interdigitated iontophoretic electrodes (Electrode 2 and
Electrode 3) placed directly on top of the stratum corneum layer of the membranes in the
donor chamber. The counter Electrode 1 with a surface area of 4 cm2 was custom fit to
the cell exactly and was separated from the ―top electrode‖ plane by 300 μm thick
TeflonR spacers. Electrodes 2 and 3 were machined out of stainless steel 316 into sets of
interdigitated comb-shaped fingers with a thickness and height of 0.05 cm, and the length
of 1.8 cm.

Figure 49: Cross-section (A) and top view with counter electrode removed (B) of the
experimental set-up: 1 — counter Electrode 1; 2 — Teflon spacer; 3 — medication; 4 — combshaped Electrodes 2 and 3; 5 — air channels through Electrodes 2–3; 6 — biological tissue
membrane; 7 — spring supports; 8 — B-Cell housing; 9 — electrical connectors to Electrodes 1–
3; 10 — receiver solution or absorbent cloth; 11 — temperature probe.
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The gaps between the adjacent electrode fingers were fixed at 20 μm. Resistance of the
electrode array in the background solution was measured at 22 k Ohm. The resulting
plane composed of Electrodes 2 and 3 allows transport of compounds at the donor
chamber in the direction perpendicular to the plane toward the stratum corneum interface,
providing a realistic model of a transdermal drug delivery with the electrical field being
applied on a medication located externally to the membrane. The cell was equipped with
a temperature probe with an accuracy ±1 °C to monitor possible Joule heating effects.
6.2.2 Experimental methods
Impedance/Dielectric Analyzer (Novocontrol GmbH, Hundsangen Germany) using ZG4
cell adapter in a two-electrode arrangement was employed to supply the excitation signals
to the electrodes; to determine the system impedance responses as a function of time, AC
voltage and frequency; and to examine impedance changes in the membranes after the
experiments. The impedance frequency scans were performed between 0.1 and 100,000
Hz with AC voltage amplitudes (peak-to-baseline) between 100 mV and 10 V and no DC
offset. This analysis was used to evaluate impedance mismatches (Clausius–Mossotti
polarization factor) between the media and the drug molecules as a function of applied
AC frequencies [34]. In the developed drug delivery model, the intention was to subject
the drugs to ―polarization‖ AC electric perturbation with a purpose of invoking a
temporary polarization on the particles, followed by a ―motivation‖ AC signal to
facilitate transport of the polarized drug through the membrane [5,6]. With that in mind,
two successive AC electric fields were created between counter Electrode 1 and
interdigitated Electrodes 2 and 3 ―shortened‖ together ―Circuit 1‖), and separated
interdigitated Electrodes 2 and 3 ―Circuit 2‖). In this delivery model the purpose of
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Circuit 1 is to invoke polarization and electrokinetic transport on the drug particles by
operating at polarization frequency determined from the Clausius–Mossotti polarization
factor analysis. Circuit 2 operates in AC iontophoretic mode influencing the particles
transdermal transport and reducing the skin resistance by electroporation mechanism
[18]. A switchboard designed ―in-house‖ transferred excitation signals between Circuits 1
and 2 with under millisecond time delay. In addition, 1200 s long control experiments
were performed, both with the drugs present at the donor chamber without any external
electrical excitations, and with Circuit 2 used to influence the drug delivery in a constant
current (0.2 mA) iontophoretic mode, similar to currents used in commercially available
iontophoretic devices. In the control experiments polarization of the drug particles
utilizing Circuit 1 was not performed.
In order to verify the effectiveness of the drug delivery through the membranes, the pig
skin and cow hoof samples were visually analyzed after each test for appearance of
residue on the receiver chamber side, and for the changes in their electrical impedance
[5–9]. The electrical impedance of the membranes was determined by the electric current
and voltage drop across the samples according to Ohm's law. The studies also included
temperature readings of the skin surface before, during and after each experimental study
to determine the effects of electrical heating. Drug throughput into the receiver chamber
was quantified using a UV–Vis concentration analysis technique in which study sample
absorbencies were fit to a linear calibration curve of standard samples. The UV–Vis
analysis (Varian Cary 300, Absorbance range 2–4 Abs; precision: ±0.002 Abs) at room
temperature was performed and calibration curves of known drug concentrations (5
samples) were developed (terbinafine at 222 nm and insulin at 271.9 nm). After each
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transdermal experiment, the receiver solution samples were collected. Three separate
aliquots were taken from each solution; each of the three aliquots was scanned three
times. The average of these nine values was used to fit the calibration curve for the peak
UV absorbance measurements for the residue samples. The average standard deviation
for the UV–Vis scans for Lamisil and Humalog® studies was 0.016 and the average
relative error of the absorbance readings was 1.8%, with a range from 0.2% to 5.2%.
Lamisil has a number of surfactants that can potentially interfere with UV–Vis
detection of terbinafine. Therefore, terbinafine transport was separately confirmed by
GC-MS (Varian 3900/Saturn 2000), in which the components of a sample are separated
and measured by their molecular mass and time of detection. The drug residue collected
from the absorbent cloths was placed in methyline chloride or hexane solvents (each
residue was dissolved in 10 mL solution and stored in30 mL amber bottles) before the
GC-MS analysis. The intensity of the peaks could then be used to calculate the amount of
terbinafine based on the standard samples.
6.2.3 Experimental design and statistical analysis
A series of studies was performed to investigate the transdermal transport and
changes in the membranes' conductivities as a function of AC voltage amplitudes and
frequencies, treatment time, and membrane thickness. This type of factorial design
identifies the most important parameters affecting drug transport and pinpoints optimal
ranges for those parameters. The resulting 53*22 factorial design with two variables at
two levels and five variables at three levels for insulin, and 43*22 for terbinafine is
summarized in table 13.

xiii

Circuit 1

Circuit 2

Membrane
Thickness
mm

Time (sec)

AC voltage
amplitude
(V)

Frequency
(Hz)

Time
(sec)

AC voltage
amplitude
(V)

Frequency
(Hz)

1

100

0.1

1.0

100

0.1

0.1

1.0

2

1200

1.0

100

1200

1.0

1.0

1.5

10

10000

10

100

2.0

Levels

3

Table 13: Factorial design for terbinafine and insulin.

This factorial design incorporates a total of 500 studies for insulin and 256 studies
for terbinafine with the data analysis performed using StatGraphics OnlineR (StatPoint
Technologies, Warrenton, VA) software. For each study two controls were incorporated,
one without any electrical excitation; and one applying constant 0.2 mA current DC
signal for 1200 s. A broader study of the effects of other input control parameters, such as
geometry of the device; thickness, type and condition of the membrane; initial amounts
and type of drugs; and localized external heating for regulating transdermal transport
through animal and human skin model is being developed at that time.

6.3 Results and Discussion
6.3.1 Simulation of the AC electrokinetic forces
Before conducting an experimental evaluation of the transdermal transport concept, a
computational model was developed taking into consideration a variety of polarization
and electrokinetic forces influencing drug particles in external non uniform AC electric
field created by the asymmetrical Electrodes 2 and 3 and counter Electrode 1. The effects
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of EP, EO, drag, and Brownian forces can be estimated from Smoluchowski, Helmholtz–
Smoluchowski, Stokes, and Brown equations for small particles, respectively [24–27].
Joule heating temperature increase resulting from the application of external electric field
can be estimated [25,26] for a fluid with conductivity σM and thermal conductivity k as
ΔT=σMERMS 2 /k, where ERMS is the root mean square value of the AC electric field
[24]. An applied electric field and resulting localized Joule heating also result in
temperature gradient in the medium and spatial variations in the conductivity,
permittivity, viscosity, and density of the solution, creating inhomogeneous coulomb and
dielectric body forces in a fluid. This phenomenon is known as the ―electrothermal
effect‖ and can induce microscale fluid motion, thereby non invasively stirring the fluid
at the microscale. An order of magnitude estimation of the electrothermal flow was
provided [25, 26] as FELTHERM=ERMS 2 1/ ε) dε/dT) / 2. The effect of the
gravitational force was assumed to be negligible.
Manipulation of biological species by DEP is one of the most broadly applied
microfluidic sorting methods. A dipole movement is induced on the biological particles
when they enter non uniform AC field. Polarized particles incur AC frequency-dependent
DEP force that is unique to the particle type and size. The time-averaged DEP force
acting on a particle with radius a is estimated asFDEP= 2πa3εMε0RE[K]gradERMS 2 .
The real part of the Clausius–Mossotti factor RE[K]=RE[ εP * −εM * )/ εP * +2εM * )]
represents the frequency-dependent mismatch in complex dielectric properties of the
media εM * ) and the particles εP * ). Variations in this factor give rise to a DEP force
that is frequency dependent and unique for a particle type. The DEP force can induce
selective particle movement to regions of high or low potential field, depending on the
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polarizability of the particles compared with that of the suspending media, and resulting
positive or negative value of the Clausius–Mossotti factor. ―Positive‖ DEP force directs
the particles toward the high potential region of the electric field, while a ―negative‖ DEP
propels the particles in the direction of decreasing field strength. The DEP mobility of a
particle scales directly with its surface area, so that to manipulate small particles larger
electric field gradients are required [34]. Thus by using a mismatch in conductivity and
permittivity values of medium and particles, submicron non polar particles can be
elegantly manipulated on planar and 3D interdigitated electrodes in steady pool and
continuous flow.
A simulation of the electric field distribution between asymmetrical electrodes
was modeled using ANSYS Multiphysics (Canonsburg, PA), a finite element software
package. A two-dimensional model was sufficient to describe the electric fields created
by Electrodes 1, 2 and 3. The result of the simulation shows that the electric field
distribution is the strongest and the electric field gradient is at its maximum in the
vicinity of the interdigitated Electrodes 2 and 3; particles which undergo positive DEP
should be attracted to those regions. These estimates were conducted for particles located
10 μm from the plane of Electrodes 2 and 3. Figure 50 shows the frequency dependence
of the Clausius–Mossotti polarization factor for insulin and terbinafine. It can be seen that
both insulin and terbinafine experience positive DEP force at frequencies under 1 MHz,
allowing to polarize and attract both drugs toward the region of higher field strength at
the edges and in the gap between Electrodes 2 and 3.
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Figure 50: AC frequency dependence for Clausius–Mossotti polarization factor for: insulin (■)
and terbinafine (▲).

In agreement with the literature data for nanometer sized particles and ~μm-sized
characteristic dimensions of irregular shaped electrodes [24–26], the estimated DEP force
is predominant for insulin particles, in particular at higher applied electric fields (Figure
51A), resulting in total insulin velocity (when all other forces are taken into
consideration) in 0.001–0.1 cm/s range for 1 to 10 V peak-to-baseline AC voltage
amplitude range (Fig. 4). The effects of other forces, in particular those of Brownian,
drag, electrothermal, and EO forces, are estimated to be negligible at AC voltages
exceeding 0.2 V. Effects of Joule electrical heating are estimated to be minimal, reaching
only ~0.01 °C at 10 V amplitude (Figure 52). Depending on the distance from the
electrode surface and the applied electric field, the combined electrokinetic forces can
transport insulin at millimeter-range distances in ~100 s. However, this effect of the DEP
electrokinetics is only an estimate fully applicable to the particles located ~10 μm from
the plane of Electrodes 2 and 3, as the predominant DEP force has a relative short-range
effect. For the particles located further in the bulk solution, the EP force, and the
concentration driven diffusion, are expected to attract the insulin particles closer to the
plane of Electrodes 2 and 3.
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Figure 51: Simulated balance of DEP (■), EP (X), EO (▲), electrothermal (●), Brownian (⋄ ),
and drag (□) forces as a function of AC amplitude for: A) insulin; B) terbinafine.

In the case of smaller and less polar terbinafine molecules, the DEP force is
predominant above 1 V (Figure 51B). At lower fields the drag and Brownian forces
become important. At higher electric fields the terbinafine particles total velocity is
influenced by a combination of EP and DEP forces achieving total particles velocity in
0.0001–0.01 cm/s range for 1 to 10 V peak-to-baseline AC voltage amplitude range
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(Figure 52). Effects of Joule electrical heating were estimated to be minimal, reaching
~0.002 °C at 10 V amplitude (Figure 51).

Figure 52: Estimated temperature increase for insulin (▯) and terbinafine (●) and total velocities
for insulin (■) and terbinafine (▲) as a function of AC voltage amplitude.

6.3.2 Insulin and terbinafine delivery results
Statistical analysis of the results transmembrane transport demonstrated a 5–9
times increase in the pig skin conductivity for insulin delivery (the mean increase was
6.78±1.45 times) and a 2–5 times increase in the cow hoof conductivity for terbinafine
delivery (the mean increase was 3.48±1.25 times) depending on the applied voltage
amplitudes and frequencies, delivery time, and the membrane's thickness. The literature
data suggests that AC and DC iontophoretic skin treatments produce reversible increases
in hydration and disorganization in the lipid bilayers of the stratum corneum, resulting in
up to three orders of magnitude decrease in the skin electrical resistance and expanded
skin porosity, leading to higher efficiency of transdermal transport [5–9]. The significant
conductivity increase was therefore taken as an initial indicator of a more facile drug
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penetration through the membranes. The statistical analysis demonstrated that this
conductivity change was driven mostly by the AC voltage amplitude and frequency of the
applied signal in Circuit 2, and the AC voltage amplitude in Circuit 1 (table 14). The
membrane's conductivity increase is higher for the lowest (0.1 Hz) frequency value and
the highest voltage amplitude (10 V) in Circuit 2, in agreement with previously reported
AC iontophoretic results [17, 18]. Delivery time (in either Circuits 1 or 2) was not found
to be a significant factor, indicating the conductivity change was driven by the effect of
the applied electric fields on the membranes, not by the mass transport mechanism. Apart
from the effects of the AC voltage amplitude that induces polarization and electrokinetic
transport on the particles, the signal parameters in Circuit 1 appear to be relatively
unimportant in affecting the membranes' conductivity change. Pre- and post-test pig skin
and cow hoof conductivity measurements for the control experiments (which applied the
drug without the electrical signal) showed less than 10% change.
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Conductivity,

Conductivity,

Throughput,

Throughput,

Cow hoof

Pig skin

Terbinafine

Insulin

-0.09

+0.11

+0.15

+0.04

+0.37

+0.56

+0.45

+0.69

Frequency

-0.12

-0.06

+0.10

+0.09

Time

-0.12

+0.09

+0.05

+0.02

+0.57

+0.66

+0.35

+0.34

-0.32

-0.49

-0.45

-0.62

N/A

-0.25

N/A

-0.68

Input
factors
Time
AC voltage
Circuit 1
Amplitude

AC voltage
Circuit 2
Amplitude
Frequency
Membrane
Thickness

Table 14: R-values for input factors dependence in changes of cow hoof and pig skin
conductivities and Terbinafine and insulin delivery throughput.

A factor analysis of the investigating variables and one outcome measure
(membranes' conductivity) finds three significant factors — Circuit 1 voltage, Circuit 2
voltage, and Circuit 2 frequency variables. The Circuit 1 voltage variable factor explains
28% (insulin) and 22% (terbinafine) of the variance in the outcome measures, Circuit 2
voltage factor explains 32% (insulin) and 42% (terbinafine), and Circuit 2 frequency
explains 22% (insulin) and 24% (terbinafine), for a total of 82% (insulin) and 88%
(terbinafine) of variance explained by the three factors. This indicates that although the
study has captured most of the major influential factors, other variables, such as
membrane thickness that was investigated only in Humalog®
experiments and showed a moderate (r= −0.25) negative effect on membrane
conductivity change, also contribute to variations in outcomes.
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The actual trans-membrane drug delivery was quantified by spectrophotometry
and GC-MS. A certain degree of uncertainty is expected from the UV–Vis analysis of the
solutions collected from the receptor compartment, as it detects only the portion of the
drug passed completely through the entire membrane; an additional portion of the drug
may be embedded in the membrane. Following the Lamisil transport tests, a residue
optically comparable to terbinafine was discovered at a receiver chamber side of the
membranes. GC-MS analysis confirmed the presence of terbinafine with essentially no
interference from the other Lamisil cream components in this residue.
Quantification of the terbinafine transport using the developed drug delivery
model demonstrated the drug delivery to the receiver side of the cow hoof membrane in
25%–53% range with a statistical mean of 39% based on an initial dose of 1%
terbinafine. Transport by weight ranged from 1.25 μg to 2.65 μg. When only Electrodes 2
and 3 were used in the iontophoresis mode at a constant current of 0.2 mA for 1200 s, the
UV–Vis analysis demonstrated 5.3% transport efficiency, similar to what was reported
before in the literature on iontophoretic delivery. The passive application of the drug
resulted in no detectable transport through the cow hoof membrane in 1200 s.
Quantification of insulin transport through the pig skin membrane demonstrated a
throughput ranging from 12% to 97%, with a statistical mean of 57% based on an initial
insulin amount of 2.85 mg in 500 μL sample. Membrane thickness has shown strong
negative correlation (r= −0.68) with throughput, indicating that thicker membranes are
more effective in impeding the insulin transport. When only Electrodes 2 and 3 were used
in the iontophoresis mode at a constant current of 0.2 mA for 1200 s, the UV–Vis
analysis demonstrated at most 2% transport efficiency (within the error of the UV-
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analysis), indicating essentially no measurable insulin transport. The passive application
of insulin resulted in no transmembrane transport improvement in 1200 s. Circuit 2
parameters affecting the transdermal transport were AC voltage and frequency, with
higher voltage amplitude and lower frequency providing a significant nearly linear
transport enhancement (Figure 53A), similarly to the previously published data [18].
For both experimental sets with Lamisil and Humalog® it was shown that the AC
frequency values for the electric signals applied in Circuit 1 played essentially no role in
the effectiveness of the drugs transport. This is not surprising considering that Clausius–
Mossotti polarization factor values for both drugs are positive and constant at frequencies
under 100 kHz, therefore including all three AC frequency values used in Circuit 1 (1,
100, and 10,000 Hz) (Figure 50). In compliance with the initial premise that the
electrokinetic forces increase either proportionally to the electric field or proportionally
to the gradient of the square of the electric field, increasing the AC voltage amplitude in
Circuit 1 resulted in an increase in throughput from 7±2% (0.1 V) to 40±13% for
terbinafine transport (10 V) in 1200 s. Increasing of the AC amplitude from 0.1 V to 10 V
(Humalog®) resulted in the increase in throughput from 10±2% to 74±20% for insulin
transport in 1200 s. Figure 53 illustrates this point by presenting the data samples for the
experiments where the thickness of the membranes was held constant at 1 mm,
operational times for both Circuits 1 and 2 at 1200 s, Circuit 1 AC frequency at 1000 Hz,
Circuit 2 AC frequency at 0.1 Hz, and Circuit 2 voltage peak-to-baseline amplitudes
variable between 1 and 10 V. Delivery times for Circuit 1 played little role in the
effectiveness of the drugs delivery, showing weak positive correlation (r=0.04 for insulin,
r=0.15 for terbinafine) with throughput, indicating that longer delivery times are
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somewhat more effective in increasing drug transport. Relative weakness this correlation
may be related to one of the computational analysis conclusions indicating that a time
period of ~100 s is largely sufficient for polarization and transport of both drugs (in
particular insulin) to the edges of Electrodes 2 and 3.
Apart from the effects of the voltage amplitudes in Circuits 1 and 2, and low
frequency values in Circuit 2 for both investigated drugs, and membrane thickness in
Humalog® studies, the investigating variables did not strongly correlate with throughput,
which was fairly consistent across study parameters. For example, for the insulin studies
half of the throughput values were between 40% and 70%, and three quarters were
between 40% and 100%. The standard deviation for throughput was 22%.
Application of higher AC electric fields can potentially cause a heating Joule
effect, especially if the media possesses abnormally high electrical and low thermal
conductivities. The temperature readings of the skin surface before, during and after each
experimental study demonstrated essentially no localized heating or visible damage to
membranes (such as burns) due to the application of the electrical fields, consistent with
the conclusions derived on the basis of the computational model (Figure 52).
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Figure 53: Drug delivery throughput results and variation by AC voltage amplitude in Circuit 1
for: A) insulin and B) terbinafine for the membranes thickness of 1 mm, Circuit 1 and Circuit 2
delivery times 1200 s, Circuit 1 AC frequency of 1000 Hz and Circuit 2 AC frequency of 0.1
Hzwere constant, Circuit 2 voltageamplitudes (■,■)10 Vand1 V(▲,▲). Iontophoresis results at
0.2 mA constant current (♦, ♦) are shown for comparison.
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Even for 10 V peak-to-baseline voltage amplitude in Circuit 2, the resulting AC
currents did not exceed 5 mA (peak-to-baseline), which is a threshold based on human
tolerance to these currents from the in vivo studies [19]. A comparable study in the
literature showed that a low voltage current at 1 V for 1 min across the stratum corneum
10 μm thick and resistance 100 k Ohm/cm) gave rise to a very moderate 0.14 °C
temperature increase [5]. However, this model assumes that all electrical energy is
dissipated and converted into heat in the skin and generally provides an overestimate in
the temperature rise. On the other hand, in the iontophoretic delivery a precaution should
always be taken to keep the voltage amplitudes reasonably low while keeping the
transdermal flux high. Due to the heterogeneity of the stratum corneum structure and
composition, current could flow through localized pathways and dissipation of the energy
could result in localized heating underestimated by calculation.
Development of microfabricated 3D interdigitated electrodes allows for a higher
throughput drug delivery system as the EP and DEP effects are enhanced. These types of
interdigitated devices show less of a decrease in the force profile with the distance above
the plane, therefore greatly improving the polarization effect and transport of the
particles. The interdigitated 3D electrodes structure also showed approximately 10 times
smaller Joule heating effect for similar conditions when compared with a 2D planar
electrodes structure [27].
Our results indicate that utilization of electric field in iontophoretic or
electroporation skin treatment, even when strong enhancement in the skin conductivity is
achieved, is insufficient for an effective transdermal delivery. The significant increase in
the membrane conductivity is not always indicative of the efficient drug transport through
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the membrane. In fact, the several studies with highest membranes conductivity increase
(up to 10 times) had relatively low throughput values, including the lowest value
recorded of 12% insulin throughput. The pathway of ion transportation induced by AC
electrokinetic forces may be somewhat different from that induced by DC iontophoresis
[17]. Non-facilitated transport across the skin can conceivably occur via transcellular,
paracellular, or appendageal paths [28]. Transport pathways are influenced by
physicochemical factors (molecular size, electric charge, concentration) and biological
factors (skin site, morphological structure, regional blood flow). Although our study does
not reveal the nature of the major transportation pathway during the AC electrokinetic
delivery of terbinafine and insulin, their molecules may be transported through not only
an appendageal path, but also a transcellular path. Additionally, we cannot deny the
possibility that an AC electric field with a certain frequency may directly open a new
pathway, leading to facilitation of ion transportation. Since structural changes in the
biological membranes during the application of AC electrokinetic treatment were not
examined in the present study, further research is needed to determine the major
transportation pathway evoked by the AC field in different biological membranes. The
effects of different biological membranes, including the human skin, will be addressed in
the future, including the effects of membrane's heterogeneity and ageing.

6.4 Conclusions
Our results indicated that a combination of two applied AC fields generating
electrokinetic and iontophoretic protocols was capable of in vitro transporting clinically
significant amounts (50–90% throughput levels) of macromolecular insulin and non polar
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terbinafine across membranes up to 2 mm thick in as little as several minutes, which is a
significant improvement over macromolecular transdermal delivery results reported in
the literature. On average, a combination of electrokinetic and iontophoretic protocols
achieved transdermal delivery enhancement of ~28 times for insulin and ~7 times for
terbinafine comparing to the iontophoretic constant current mode, and even better
enhancement over the passive diffusion transdermal drugs application. This adaptable
new method of drug transport was capable of motivating chemical compounds that are
difficult to transport non invasively because of their large molecular size and non ionic
structure. This is accomplished through the use of electrokinetic forces in interdigitated
electrodes applying a non uniform AC electric field to a chemical compound, inducing an
electrical field gradient that provides an electromotive force variable in magnitude and
direction with applied frequency and field strength. Macromolecular drugs are thus
polarized, and their iontophoretic transmembrane delivery is controlled by a second AC
field. Applied AC voltage amplitude which polarizes the drugs, AC voltage amplitude
and frequency inducing iontophoretic and electroporation effects, and the
membrane's thickness were the most significant factors in affecting the throughput.
It is important to state that stand alone constant current iontophoretic mode
application unsupported by electrokinetic polarization and manipulation of the drugs was
generally unsuccessful in transdermal transport of insulin and terbinafine. Therefore the
iontophoretic and electroporation enhancements of transmembrane delivery should be
combined with electrokinetic polarization of non polar macromolecular drugs. The full
magnitude of effects of the electrodes geometry and polarity; delivery time; medication
chemical properties and composition; type, hydration, porosity, surface charge and
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condition of biological tissue membranes; AC voltage amplitude and frequency on the
efficiency of the electrokinetic drug transport is yet to be investigated. Continuing our
work in optimization of combination (either sequential or simultaneous operation) of
optimally- tuned AC electrical fields is needed for inducing polarization and enhancing
transport to deliver macromolecules through biological membranes. On the basis of these
principles, a non-invasive transdermal method capable of delivering non polar high
molecular weight drugs appears to be feasible. This method has a potential for producing
clinical products for efficient, facile, controlled and safe transdermal drug delivery.
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